专利摘要:
Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R13, Ra, Rb, A and n are as defined in the description. Drugs.
公开号:FR3037957A1
申请号:FR1555752
申请日:2015-06-23
公开日:2016-12-30
发明作者:Zoltan Szlavik；Andras Kotschy；Maia Chanrion；Didier Demarles；Olivier Geneste；James Edward Paul Davidson；James Brooke Murray；Szabolcs Sipos；Attila Paczal；Balazs Balint
申请人:Laboratoires Servier SAS；Vernalis R&D Ltd；
IPC主号:

专利说明:

[0001] The present invention relates to novel hydroxyester derivatives, process for their preparation and pharmaceutical compositions containing them. The compounds of the present invention are new and have very interesting pharmacological characteristics in the field of apoptosis and oncology. Apoptosis, or programmed cell death, is a crucial physiological process for embryonic development and maintenance of tissue homeostasis. Apoptotic cell death involves morphological changes, such as core condensation, DNA fragmentation, as well as biochemical phenomena, such as activation of caspases that will degrade key structural components of the cell to induce disassembly and death. The regulation of the apoptosis process is complex and involves the activation or repression of several intracellular signaling pathways (Cary S. et al., Nature Review Cancer, 2002, 2, 647-656).
[0002] Deregulation of apoptosis is implicated in certain pathologies. Increased apoptosis is linked to neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and ischemia. Conversely, deficiencies in the execution of apoptosis play an important role in the development of cancers and their chemoresistance, autoimmune diseases, inflammatory diseases and viral infections. Thus, the absence of apoptosis is part of the phenotypic signatures of cancer (Hanahan D. et al., Cell 2000, 100, 57-70). The anti-apoptotic proteins of the Bel-2 family are associated with numerous pathologies. The involvement of Bel-2 family proteins is described in many types of cancer, such as colon cancer, breast cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphocytic leukemia, lymphoma, myeloma, acute myeloid leukemia, pancreatic cancer, etc. Overexpression of anti-apoptotic proteins of the Bc1-2 family is implicated in tumorigenesis, chemotherapy resistance, and clinical prognosis in cancer patients.
[0003] In particular, Mc1-1, a member of the Bel-2 anti-apoptotic family, is overexpressed in various types of cancers (Beroukhim R. et al., Nature 2010, 899-905). There is therefore a therapeutic need for compounds that inhibit the anti-apoptotic activity of Bel-2 family proteins. The compounds of the present invention, in addition to novelty, have pro-apoptotic properties for use in pathologies involving a lack of apoptosis, for example in the treatment of cancer and autoimmune diseases and the immune system. The present invention relates more particularly to compounds of formula (I): Ra Rb (I) wherein: - A represents the group where 1 is bonded to the oxygen atom and 2 is bonded to the phenyl ring, - R1 represents a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a linear or branched C2-C6 alkynyl group, a linear or branched C1-C6 alkoxy group, a -S- group ( C1-C6 alkyl), a linear or branched C1-C6 polyhaloalkyl, a hydroxy group, a hydroxy (C1-C6) alkyl group, a cyano group, -Cy6 or a halogen atom, R2, R3 , R4 and R5 independently of one another represent a hydrogen atom, a halogen atom, a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a C2-C2 alkynyl group, C6 3037957 - 3 - linear or branched, a polyhaloalkyl C1 linear or branched C6, a hydroxy group, a hydroxy (C1-C6) alkyl group, a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group, a cyano group, a nitro group - (C6-C6) alkyl-NR9R9 ', -O- (C1-C6) alkyl -NR9R9', -O- (C1-C6) alkyl-R10, -C (O) -OR9 , -OC (O) -R9, -C (O) -NR9R9 ', -NR9-C (O) -R9', -NR9-C (O) -OR9 ', - (C1-C6) alkyl-NR9 -C (O) -R9 ', -SO2-NR9R9', -SO2- (C1-C6) alkyl, or the substituents of one of the (R2, R3), (R3, R4), (R4, R5) ), when grafted onto two adjacent carbon atoms, together with the carbon atoms carrying them form an aromatic or nonaromatic 5 to 7-membered ring, which may contain from 1 to 3 heteroatoms selected from oxygen , sulfur and nitrogen, it being understood that the resulting ring may be substituted by a group selected from a linear or branched C1-C6 alkyl group, -NR1- (C1-C6 alkyl) -Cyi or an oxo, R6 and R7 represent, independently of one another, a hydrogen atom, a halogen atom, a linear or branched C1-C6 alkyl group or a linear or branched C2-C6 alkenyl group; , a linear or branched C2-C6 alkynyl group, a linear or branched C1-C6 polyhaloalkyl group, a hydroxyl group, a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group; ), a cyano group, a nitro group, - (C6-C6) alkyl -NR9R9 ', -O- (C1-C6) alkyl -NR9R9', -O-Cy1, - (C1-C6) alkyl - -CY 1, -C 2 -C 6 alkenyl -C 1 -C 6 -C 2 -C 6 alkynyl -C 1 0 -O- (C 1 -C 6) alkyl-R 10 -C (O) -OR 9, -O-C (0) -R9, -C (O) -NR9R9 ', -NR9-C (O) -R9', -NR9-C (O) -OR9 ', -C1-C6alkyl -NR9-C ( 0) -R9 ', -SO2-NR9R9', -SO2- (C1-C6) alkyl, or the substituents of the (R6, R7) pair, when grafted onto two adjacent carbon atoms, form together with carbon atoms carrying them an aromatic or nonaromatic ring consisting of 5 to 7 members, which may contain from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, it being understood that the resulting ring may be substituted by a group selected from a linear or branched C 1 to C 6 alkyl group, -NR 1 R 11 ', - (C 1 -C 6) alkyl-Cyl or an oxo, R 8 represents a linear or branched C 1 to C 6 alkyl group, a C 2 to C 6 alkenyl group. Linear or branched C6, linear or branched C2-C6 alkynyl, -Cy3, -C1-C6alkyl -Cy3, -C2-C6alkenyl -Cy3, -C- C2-C6 alkynyl) -Cy3, -Cy3-Cy4, a - (C2-C6) alkynyl-O-Cy3, -Cy3 --- (C1-C6) alkyl-O- (C1-C6) alkyl) -Cy4, a halogen atom, a cyan group, -C (O) -R12 or -C (O) -NR12R12 ', 5 -R9 and R9' represent, independently of one another, a hydrogen atom , a linear or branched C1-C6 alkyl group, a - (alkyl) in C6-C6) -CY1, or the substituents of the pair (R9, R9 ') together with the nitrogen atom carrying them an aromatic or non-aromatic ring consisting of 5 to 7 members, which may contain in addition to the nitrogen atom of 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom or an alkyl group; C1 to C6 linear or branched, and with the proviso that the carbon atom (s) of the possible substituents can be deuterated, R10 is -Cyl, -Cyl- (C1-C6) alkyl -Cy2, -Cy1- ( C1-C6alkyl) -O- (C1-C6) alkyl-C2y, -Cy1- (C1-C6) alkyl-NR9- (C1-C6) alkyl -Cy2, -Cy1-Cy2-O- ( (C1-C6) alkyl-Cys, -C (O) -NR9R9 ', -NR9R9', -OR9, -NR9-C (O) -R9 ', -O- (C1-C6) alkyl-OR9, - S02-R9, -C (O) -OR9 or -NH-C (O) -NH-R9, -R11, R11 ', R12 and R12' independently of one another represent a hydrogen atom or a optionally substituted linear or branched C1-C6 alkyl group; - R13 represents a hydrogen atom, a hydroxy group or a hydroxy (C1-C6) alkyl group; - Ra represents a hydrogen atom or an alkyl group; C1 to C6 linear or branched, Rb represents a group -O-C (O) -O-Re, a group -O-C (O) -NReR0 'or a group -OP (O) (OR0) 2, - Re and Re 'represent, independently of one another, a hydrogen atom, a linear or branched C1-C8 alkyl group, a cycloalkyl group or a (C1-C6) alkoxy (C1-C6) alkyl group; ), a (C1-C6) alkoxycarbonyl (C1-C6) alkyl group, or the substituents of the (Re, Re ') pair together with the nitrogen atom bearing them a non-aromatic ring consisting of 5 to 7-membered ring, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen, it being understood that the nitrogen in question may to be substituted by a group representing a linear or branched C1-C6 alkyl group; - Cy1, Cy2, Cy3, Cy4, Cys and Cy6 independently of one another represent a cycloalkyl group, a heterocycloalkyl group, an aryl group or a group heteroaryl, n is an integer equal to 0 or 1, it being understood that: "aryl" means a phenyl, naphthyl, biphenyl, indanyl or indenyl group, "heteroaryl" means any mono- or bicyclic compound consisting of 5 to 10 members, having at least one aromatic group and containing from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, "cycloalkyl" means any nonaromatic carbocyclic group, mono- or bi-cyclic, containing from 3 to 10 members, by "heterocycloalkyl" is meant any nonaromatic carbocyclic group, mono- or bi-cyclic, consisting of 3 to 10 members and containing from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, which may comprise fused, bridged or spiro ring systems, with the possibility for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups thus defined and the alkyl, alkenyl and alkynyl groups, alkoxy, to be substituted with 1 to 4 groups selected from optionally substituted linear or branched C1 to C6 alkyl, optionally substituted linear or branched C2 to C6 alkenyl, optionally substituted linear or branched C2 to C6 alkynyl, C1 to C6 alkoxy; C6 linear or branched optionally substituted, (C1-C6) alkyl-S- optionally substituted, hydroxy, oxo (or N-oxide if appropriate), nitro, cyan, -C (O) -OR ', -OC ( 0) -R ', -C (O) -NR'R ", -NR'R", linear or branched C1-C6 polyhaloalkyl, trifluoromethoxy or halogen, it being understood that R' and R "independently represent one on the other a hydrogen atom or an alkyl group C1 to C6 linear or branched optionally substituted, and it being understood that the carbon atom (s) of the preceding possible substituents may be deuterated, their enantiomers, diastereomers and atropisomers, and their addition salts with an acid or a pharmaceutically acceptable base. Among the pharmaceutically acceptable acids, mention may be made, without limitation, of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphonic acid, acetic acid, trifluoroacetic acid and lactic acid. , pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid , methanesulfonic acid, camphoric acid, etc. Pharmaceutically acceptable bases include, but are not limited to, sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine and the like. Advantageously, at least one of the groups chosen from R2, R3, R4 and R5 does not represent a hydrogen atom. More particularly, the compounds of formula (I) which are given preference are the compounds in which n is an integer equal to 1.
[0004] In another embodiment of the invention, an advantageous possibility is composed of the compounds of formula (Ia): wherein R1, R2, R3, R4, R5, R6, R7, Ra, Rb, R13 and A are such than defined for formula (I). In the preferred compounds of the invention, R1 represents a linear or branched C1-C6 alkyl group or a halogen atom. More preferably, R 1 represents a methyl group, an ethyl group, a bromine atom or a chlorine atom. Atropisomers are stereoisomers that occur due to impeded rotation around a single bond, where energy differences due to steric tension or other contributors create a barrier to rotation that is high enough to allow the isolation of individual conformers. For the compounds according to the invention, the atropisomers are as follows: The preferred atropisomer is (5Sa). Preferably, R13 represents a hydrogen atom. Advantageously, R2 represents a halogen atom, a hydroxyl group or a linear or branched C1-C6 alkoxy group. More preferably, R2 is methoxy, hydroxy, fluoro, bromo or chloro. Even more preferably, R2 represents a chlorine atom.
[0005] Advantageously, R3 represents a hydrogen atom, a hydroxy group, a linear or branched C1-C6 alkoxy group or -O- (C1-C6) alkyl -NR9R9 '. Advantageously, R 3 represents -O- (C 1 -C 6) alkyl -NR 9 R 9 '. In certain preferred embodiments of the invention, wherein R1, R9 and R9 'are as defined for formula (I). In the preferred compounds of the invention, where R 9 and R 9 'are as defined for formula (I). R4 and R5 preferably represent a hydrogen atom. In an advantageous embodiment, the substituents of the (R1, R5) pair are identical and the substituents of the (R2, R4) pair are identical. In the preferred compounds of the invention, the substituents of the (R1, R5) pair are identical and represent a C1-C6 alkyl group, while the substituents of the (R2, R4) pair are identical and represent an atom of halogen or a hydrogen atom. In another embodiment of the invention, R6 represents an optionally substituted linear or branched C1-C6 alkoxy group or a group -O- (C1-C6) alkyl-R10. Advantageously, R6 represents a 2,2,2-trifluoroethoxy group, a methoxy group, a 2-methoxyethoxy group or a -O- (C1-C6) alkyl-R10 group. R7 preferably represents a hydrogen atom.
[0006] In the preferred compounds of the invention, wherein R 10 is as defined for formula (I).
[0007] In another embodiment of the invention, an advantageous possibility is composed of the compounds of formula (1-b): ## STR1 ## wherein R 1, R 6, R 9, R 9, Ra, Rb R13 and A are as defined for formula (I). In the preferred compounds of the invention, R8 represents a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a linear or branched C2-C6 alkynyl group, an aryl group or a group heteroaryl. Advantageously, R8 represents a linear or branched C2-C6 alkynyl group, an aryl group or a heteroaryl group. More preferably, R8 is a prop-1-yn-1-yl group, a-1-yl-1-yl group, a phenyl group or a furan-2-yl group. In a more preferred embodiment, Rg is a 4- (benzyloxy) phenyl group, a 4- (pyridin-4-ylmethoxy) phenyl group, a 4-phenylbut-1 -yn-1-yl group, a -fluorophenyl or a 5-fluorofuran-2-yl group. Even more preferably, R8 represents a 4-fluorophenyl group. In the preferred compounds of the invention, R 9 and R 9 'are independently of each other a linear or branched C 1 -C 6 alkyl group, or the substituents of the (R 9, R 9') pair form together with the nitrogen atom bearing them a 5- to 7-membered non-aromatic ring which may contain in addition to the nitrogen atom from 1 to 5 heteroatoms selected from oxygen, sulfur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom or a linear or branched C1-C6 alkyl group. More preferably, R 9 and R 9 'represent a methyl group, or the substituents of the (R 9, R 9') pair together form a 4-methyl-piperazinyl or 4-ethyl-piperazinyl group. In a more preferred embodiment, the substituents of the (R9, R9 ') pair together form a 4-methyl-piperazinyl group. In another preferred embodiment, R9 and R9 'represent a methyl group. Advantageously, R10 represents -Cyl, -Cyr (C6-C6) alkyl-O- (C6-C6) alkyl-Cγ2 or -Cyi- (C6-C6) alkyl -Cy2. More particularly, Rio represents -Cyl, -Cyi-O-CH2-Cy2 or -Cy1-Cy2. Preferably, Cy 1 represents a heteroaryl group, in particular a pyrimidinyl group, a pyrazolyl group, a triazolyl group, a pyrazinyl group or a pyridinyl group. More preferably, Cy 1 represents a pyrimidin-4-yl group, a pyrazol-5-yl group, a triazol-5-yl group, a pyrazin-2-yl group or a pyridin-4-yl group. In the preferred compounds of the invention, Cy 1 represents a pyrimidin-4-yl group. In another embodiment of the invention, Cy 1 represents a heteroaryl group which is substituted by an optionally substituted linear or branched C1 to C6 alkyl group, an optionally substituted linear or branched C1 to C6 alkoxy group, a NR'R "or a linear or branched C1-C6 polyhaloalkyl group, it being understood that R 'and R" represent, independently of one another, a hydrogen atom or an optionally linear or branched C1-C6 alkyl group substituted. Cy2 preferably represents a phenyl group, a pyridinyl group, a pyrazolyl group, a morpholinyl group, a furanyl group or a cyclopropyl group. More preferably, Cy2 represents a phenyl group, a pyridin-2-yl group, a pyridin-3-yl group, a pyridin-4-yl group, a pyrazol-1-yl group, a morpholin-4-yl group, a furan-2-yl group or a cyclopropyl group. In the preferred compounds of the invention, Cy2 represents a phenyl group. Other compounds of the invention to which preference is given are those in which R10 is -Cy1-Cy2 where Cy1 is a pyrimidinyl group and Cy2 is a phenyl group, a pyridinyl group, a pyrazolyl group, a morpholinyl group, a group furanyl or a cyclopropyl group. More preferably, R 1 represents R 14 and R 15 represent, independently of one another, a hydrogen atom, an optionally substituted linear or branched C 1 -C 6 alkyl group or a linear or branched C 1 -C 6 alkoxy group. optionally substituted, a hydroxy group, a linear or branched C1-C6 polyhaloalkyl group or a halogen atom. Preferred R14 and R15 groups are: hydrogen; methyl; ethyl; methoxy; ethoxy; isopropoxy; methoxyethoxy; fluorine; hydroxyl; trifluoromethyl. Advantageously, R15 represents a hydrogen atom and R14 is located in the ortho position of the phenyl group. Specifically, the compounds of formula (I) to which preference is given are compounds wherein Ra represents a hydrogen atom or a methyl group. Advantageously, Rb represents a -O-C (O) -O-C 1 -C 6 alkyl group; a -O-C (O) -O-cycloalkyl group; a group -O-C (O) -NR, Re ', where Re and Re' represent, independently of one another, a hydrogen atom, a linear or branched C1-C8 alkyl group, a group ( C1-C6 alkoxy) (C1-C6) alkyl, (C1-C6) alkoxycarbonyl (C1-C6) alkyl, or the substituents of the (K, Ra ') pair together with the nitrogen carrying them a 5- to 7-membered non-aromatic ring which may contain in addition to the nitrogen atom 1 to 3 heteroatoms selected from oxygen and nitrogen; or a group -O-P (0) (01-1) 2. Among the preferred compounds of the invention, mention may be made of: - (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-442- (4-methylpiperazine-1-hypethoxyl); 5-phenyl-6- (4-fluorophenyl) thieno [2,3-pyrimidin-4-yl] oxy-3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxy} phenylpropanoate 1 Kmethoxycarbonypoxylethyl; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxylphenyl} -6- (4-fluorophenyl); 1 - [(ethoxycarbonyl) oxy] ethyl) thieno [2,3-d] pyrimidin-4-yloxy] -3- (2 - {{2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxylphenyl) propanoate (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-4- {2- (4-methylpiperazin-1-yl) ethoxyphenyl} -6- 1- (R-propan-2-yloxy) fluorophenyl) thieno [2,3-d] pyrimidin-4-yloxy) -3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxylphenyl) propanoate ) carbonylioxy} ethyl; (2R) -2 - {[(5S) -5- (3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl} -6- fluorophenyl) thieno [2,3-d] pyrimidin-4-yl] oxy} -3 1- [4- (tert-butoxycarbonyl) oxy] ethyl (1- {[2- (2-methoxyphenyl) pyrimidin-4-yl} methoxylphenyl) propanoate; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl} -6- (4-fluorophenyl) thieno 1- {[(cyclopentyloxy) carbonyl] oxylethyl [2,3-cflpyrimidin-4-yl] oxy} -3- (2 - {{2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxylphenyl) propanoate; (2R) -2 - {[(5S) -5- {3-chloro-2-inethyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl} -6- (4-fluorophenyl) 1- (Roctyloxy) carbonyl} oxy-thieno [2,3-d] pyrimidin-4-yloxy-3- [2- (2-methoxyphenyl) pyrimidin-4-yl] methoxy} phenyl) propanoate } ethyl; (2R) -2 - {{(5S) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxyl-phenyl] -6- (4-fluorophenylthieno [2], 3-Cyclopyrimidin-4-yloxy} -3- (2 - {{2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxylphenyl) propanoate 1-trimethylcarbamoyloxyethyl; (2R) -2 - {{(5)} Sa) -5 {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxyl-phenyl-6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yl] oxy} - 1 - [(diethylcarbamoyl) oxy] ethyl 3 - (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxy} phenylpropanoate; - morpholine-4-carboxylate of 1 - {[(2R)} -2 - {[(55 ') - 5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yethoxy) phenyl} -6- (4-fluorophenyl) thieno [2,3-c] pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) pyrimidin-4-yl] methoxy} phenyl) propanoyloxy} ethyl; (2R) -2- {[(5S); ) -5- {3-chloro-2-methyl-442- (4-methyl-p-erazin-1-yl) -ethoxy} -phenyl} -6- (4-fluorophenyl) thieno [2,3-d] pyrimidine; 4-yloxy} -3 - (2 - {[2- (2-methoxyphenyl) -3-pyrene) 1 - {[(2-methoxyethypcarbamoyl) oxylethyl) imin-4-yl] methoxy} phenyl) propanoate; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-412- (4-methylpiperazin-1-yl) ethoxy] phenyl} -6- (4-fluorophenyl) - thieno [2,3-d] pyrimidin-4-ylloxyl-3 - (2- {[2- (2-methoxyphenyl) -5-pyrimidin-4-yl] methoxy} phenyl) propanoate of 1- {[bis (2- methoxyethyl) carbamoyl] oxy} -ethyl; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl} -6- (4-fluorophenylthieno [2 1 - {[(2-methoxy) -3-b] pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxy} phenyl) propanoate; 2-oxoethyl) (methyl) carbamoyloxy} ethyl; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-hypethoxyl); phenyl-6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yloxy) -3 - (2- (2- (2-methoxyphenyl) pyrimidin-4-yl] methoxy} phenyl) propanoate (2-phosphonooxy) methyl (2R) -2- {[5- {2,6-dimethyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl} -644-fluorophenyl) thieno [2] 3 - [(ethoxycarbonypoxy) ethyl) pyridin-4-yl] oxyl-3 - (2 - {[2- (2-methoxyphenyl) pyrimidin-4-yl] methoxy} phenyl) propanoate; (2R) -2- { [5 - {3,5-Dichloro-2,6-dimethyl-442- (4-methylPiperazin-1-yl) ethoxy] phenyl} -6- (4-fluorophenyl) thieno [2,3 -4-pri] di n-4-ylioxy} -3 - (2- {[2- (2-methoxyphenyl) 1) - pyrimidin-4-yl] methoxy} phenylpropanoate of 1 - [(ethoxycarbonyl) oxy] ethyl; (2R) -2 - {[5-12,6-dimethyl-442- (4-methylpiperazin-1-yl) ethoxylphenyl} -6- (4-fluorophenyl) thieno [2,3-d] pyrimidine; 1 - [(Dimethylcarbamoydoxy) ethyl) 4-ylioxy} -3- (2 - {[2- (2-methoxyphenyl) pyrimidin-4-yl] methoxylphenyl) propanoate; - (2R) -2- {[5- { 3,5-dihydro-2,6-dimethyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl-6- (4-fluorophenyl) thieno [2,3-cipyrimidin-4-yl] oxy 1 - [(dimethylcarbamoydoxy) ethyl) -2- {[2- (2-methoxyphenyl) pyrimidin-4-yl] methoxylphenyl) propanoate The invention also relates to a process for the preparation of compounds of the formula ( I), said process being characterized in that it uses, as starting compound, the compound of formula (II): ## STR3 ## where A is as defined for the formula (I) in which 1 is linked to the chlorine atom and 2 is bonded to the bromine atom, said compound of formula (11) being subjected to a coupling with a compound of formula (III): Where R6, R7, R13 and are as defined for formula (I), and Alk represents an optionally substituted linear or branched C1-C6 alkyl group to give the compound of formula (IV): where R6, R7, R13, A and n are as defined for formula (I), and Alk is as defined above, the compound of formula (IV) being further subjected to coupling with a compound of formula (V): Alk R6 O 0 OAc R13 Alk Wherein R 1, R 2, R 3, R 4 and R 5 are as defined for formula (I), and RBI and RB 2 represent an atom hydrogen, a linear or branched C1-C6 alkyl group, or RBI and RB2 form with oxygen carrying them an optionally methylated ring, to obtain the compound of formula (VI): Alk R6 R13 (VI) wherein R1, R2, R3, R4, R5, R6, R7, R13, A and n are as defined for the formula (I) and Alk is as defined above, the ester function Alk-OC (O) - of the compound of formula (VI) being hydrolyzed to give the carboxylic acid (VII): wherein R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 13, A and n are as defined for formula (I) ), which is coupled with a compound of formula (VIII): Rb (VIII) Ra where Ra and Rb are as defined for formula (I), to obtain the compound of formula (I), which may be purified by a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers by a conventional separation technique, it being understood that At any time deemed appropriate during the process described above, certain (hydroxy, amino ...) groups of the starting reagents or synthetic intermediates may be protected, then deprotected and functionalized for the purpose of synthesis. The compounds of formulas (II), (III), (V) and (VIII) are either commercially available or are accessible to those skilled in the art by conventional chemical reactions and described in the literature.
[0008] The invention also relates to a compound of formula (VIA), a particular case of compound of formula (V1): Where: R2 ', R3', R4 'and R5' independently represent another a halogen atom, a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a linear or branched C2-C6 alkynyl group, a linear C1-C6 polyhaloalkyl or branched, a hydroxy group, a hydroxy (C1-C6) alkyl group, a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group, a cyano group, a nitro group, (C 1 -C 6 -alkyl) -NR 9 R 9 ', -O- (C 1 -C 6) alkyl -NR 9 R 9', -O- (C 1 -C 6) alkyl-R 10, -C (O) -OR 9, -OC ( 0) -R9, -C (O) -NR9R9 ', -NR9-C (O) -R9', -NR9-C (O) -OR9 ', -C1-C6alkyl -NR9-C (O) ) -R9 ', -SO2-NR9R9', -SO2- (C1-C6) alkyl, -T represents a C1-C6 alkyl group, a (C1-C6 carbonyloxy) group (alk C1 to C6) or di (C1 to C6) alkylaminocarbonyl (C1 to C6) alkyl, - R1, R6, R7, R13, A and n are as defined for formula (I), its enantiomers, diastereoisomers and atropisomers, and its addition salts with a pharmaceutically acceptable acid or base, as a synthetic intermediate but also as a compound for its use as pro-apoptotic agents. The invention relates to a compound of formula (VIIA), a particular case of the compound of formula (VII): where: R2 ', R3', R4 'and R5' independently represent another a halogen atom, a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a linear or branched C2-C6 alkynyl group, a linear C1-C6 polyhaloalkyl or branched, a hydroxy group, a hydroxy (C 1 -C 6) alkyl group, a linear or branched C 1 -C 6 alkoxy group, a -S- (C 1 -C 6) alkyl group, a cyano group, a nitro group, (C1-C6) alkyl -NR9R9 ', -O- (C1-C6) alkyl -NR9R9', -O- (C1-C6) alkyl-R10, -C (O) -OR9, -O- C (O) -R9, -C (O) -NR9R9 ', -NR9-C (O) -R9', -NR9-C (O) -OR9 ', - (C1-C6) alkyl-NR9-C (0) -R, ', -SO2-NR9R9', -SO2- (C1-C6) alkyl, -R1, R6, R7, R13, A and n are as defined for formula (I), its enantiomers , diastere isomers and atropisomers, and its addition salts with a pharmaceutically acceptable acid or base, as a synthetic intermediate but also as a compound for its use as pro-apoptotic agents. Advantageously, for the compounds of formula (VIA) and (VIIA), the substituents of the pair (R1, R5 ') are identical and the substituents of the pair (R2', R4 ') are identical.
[0009] A preferred compound of formula (VITA) is (2R) -2 - {[5- {3,5-dichloro-2,6-dimethyl-442- (4-methylpiperazin-1-yl) ethoxyl phenyl} 6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) pyrimidin-4-yl] niethoxylphenyl} propanoic acid . The invention also relates to a compound of formula (VIe), a particular case of the compound of formula (VI): embedded image in which: R 5 'represents a halogen atom, a C 1 to C 6 alkyl group; Linear or branched C6, a linear or branched C2 - C6 alkenyl group, a linear or branched C2 - C6 alkynyl group, a polyhaloalkyl group. C1 to C6 linear or branched, a hydroxyl group, a hydroxy (C1-C6) alkyl group, a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group, a cyano group, a nitro group - (C 1 -C 6 alkyl) -NR 9 R 9 ', -O- (C 1 -C 6) alkyl -NR 9 R 9', 10 -O- (C 1 -C 6) alkyl-R 10, -C (O) - OR9, -OC (O) -R9, -C (O) -NR9R9 ', -NR9-C (O) -R9', -NR9-C (O) -OR9 ', - (C1-C6) alkyl - NR9-C (O) -R9 ', -SO2-NR9R9', -SO2- (C1-C6) alkyl, -T represents a C1-C6 alkyl group, a (C1-C6) carbonyloxy (C1-C6) alkyl group; C1 to C6) or a di (C1-C6 alkyl) aminocarbonyl (C1-C6) alkyl group, - R1, R3, R6, R7, R13, A and n are as defined for formula (I), and where the substituents of the (R 1, R 5 ') pair are identical, its enantiomers, diastereoisomers and atropisomers, and its addition salts with a pharmaceutically acceptable acid or base, as a synthetic intermediate but also as laid out for its use as pro-apoptotic agents. The invention relates to a compound of formula (VIII), a particular case of the compound of formula (VII): ## STR2 ## where: R 5 'represents a halogen atom, a linear C 1 to C 6 alkyl group or branched, a linear or branched C2 to C6 alkenyl group, a linear or branched C2 to C6 alkynyl group, a linear or branched C1 to C6 polyhaloalkyl, a hydroxy group, a hydroxy (C1 to C6) alkyl group a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group, a cyano group, a nitro group, - (C1-C6) alkyl -NR9R9 ', -O- (alkyl) C1 to C6) -NR9R9 ', -O- (C1-C6) alkyl-R10, -C (O) -OR9, -OC (O) -R9, -C (O) -NR9R9', -NR9- C (O) -R9 ', -NR9-C (O) -OR9', - (C1-C6) alkyl -NR9-C (O) -R9 ', -SO2-NR9R9', -SO2- (alkyl) C1 to C6), - R1, R3, R6, R7, R13, A and n are as defined for formula (1), and where the substituents of the pair (R1, R5 ') are identical, its enantiomers, diastereoisomers and atropisomers, and its addition salts with a pharmaceutically acceptable acid or base, as a synthetic intermediate but also as a compound for its use as pro-apoptotic agents. A preferred compound of formula (VIIB) is (2R) -2-115- {2,6-dimethyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl} -6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yl] oxy) -3- (2 - {[2- (2-methoxyphenyl) pyriol-4-ylmethoxy} phenyppropanoic acid The pharmacological study of the compounds The ability to reactivate the apoptotic process in cancer cells is of major therapeutic interest in the treatment of cancers and autoimmune diseases and the immune system.
[0010] In particular, the compounds of the invention will be useful in the treatment of chemo- or radioresistant cancers. Among the treatments for the cancers contemplated, mention may be made of, but not limited to, the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemias, colon cancers, esophagus and liver, lymphoblastic leukemias, acute myeloid leukemias, lymphomas, melanomas, hematological malignancies, myeloma, ovarian cancer, non-small cell lung cancer, prostate, pancreatic cancer and small cell lung cancer. The present invention also relates to pharmaceutical compositions containing at least one compound of formulas (I), (VIA), (VIB), (VIIA) or (VIIB) in combination with one or more pharmaceutically acceptable excipients. Among the pharmaceutical compositions according to the invention, mention may be made, more particularly, of those which are suitable for oral, parenteral, nasal, per- or trans-cutaneous, rectal, perlingual, ocular or respiratory administration and in particular simple or sugar-coated tablets. , sublingual tablets, sachets, packets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels and oral or injectable ampoules. The dosage varies according to the sex, age and weight of the patient, the route of administration, the nature of the therapeutic indication, or possibly associated treatments, and ranges from 0.01 mg to 1 g per 24 hours. hours in one or more 20 administrations. In addition, the present invention also relates to the combination of a compound of formulas (I), (VIA), (VIB), (VIIA) or (VIIB) with an anti-cancer agent chosen from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors and antibodies, as well as pharmaceutical compositions containing this type of combination and their use in the manufacture of medicaments for use in the treatment of cancer. Advantageously, the present invention relates to the combination of a compound of formulas (I), (VIA), (VIB), (VIIA) or (VIIB) with an EGFR inhibitor, as well as pharmaceutical compositions comprising this compound. type of association.
[0011] In another embodiment, the present invention relates to the combination of a compound of formulas (I), (VIA), (VIB), (VIIA) or (VIIB) with a mTOR inhibitor. PI3K, as well as pharmaceutical compositions comprising this type of combination. In a preferred embodiment, the present invention relates to the combination of a compound of formulas (I), (VIA), (VIB), (VIIA) or (VIIB) with an MEK inhibitor, as well as the compositions pharmaceutical companies including this type of association. Preferably, the present invention relates to the combination of a compound of formulas (I), (VIA), (Vin), (VIIA) or (VIIB) with a HER2 inhibitor, as well as pharmaceutical compositions comprising this type Association. Advantageously, the present invention relates to the combination of a compound of formulas (I), (VIA), (VIB), (VIIA) or (VIIB) with an RAF inhibitor, as well as pharmaceutical compositions comprising this compound. type of association. In another embodiment, the present invention relates to the combination of a compound of formulas (I), (VIA), (VIB), (VIIA) or (VIIB) with an EGFR / HER2 inhibitor, as well as pharmaceutical compositions comprising this type of combination. In a preferred embodiment, the present invention relates to the combination of a compound of formulas (I), (VIA), (VIn), (VIIA) or (VIIB) with a taxane, as well as pharmaceutical compositions comprising this compound. type of association. In another embodiment, the present invention relates to the combination of a compound of formula (I), (VIA), (VIB), (VIIA) or (VIIB) with a proteasome inhibitor, an immunomodulator or a alkylating agent, as well as pharmaceutical compositions comprising this type of combination. The combination of a compound of formulas (I), (VIA), (VIB), (VILA) or (VIIB) with an anticancer agent may be administered simultaneously or sequentially. The route of administration is preferably oral, and the corresponding pharmaceutical compositions may allow instantaneous or delayed release of the active ingredients. In addition, the compounds of the combination may be administered in the form of two separate pharmaceutical compositions, each containing one of the active ingredients, or in the form of a single pharmaceutical composition in which the active ingredients are mixed. The compounds of the invention may also be used in combination with radiotherapy in the treatment of cancer. Finally, the compounds of the invention may be bound to monoclonal antibodies or fragments thereof or may be linked to framework proteins that may or may not be related to monoclonal antibodies. By antibody fragments are meant fragments of the type Fv, scFv, Fab, F (ab ') 2, F (ab'), scFv-Fc, or diabodies, which in general have the same binding specificity. than the antibody from which they are derived. According to the present invention, the antibody fragments of the invention can be obtained from antibodies by methods such as digestion with enzymes, such as pepsin or papain, and / or by cleavage of the disulfide bridges by reduction. chemical. In another way, the antibody fragments included in the present invention can be obtained by genetic recombination techniques also well known to those skilled in the art or by peptide synthesis using automatic peptide synthesizers for example, such as than those provided by Applied Biosystems, etc. Structural proteins which may or may not be related to monoclonal antibodies are proteins which contain, or do not contain, immunoglobulin folding and which exhibit binding capacity similar to that of a monoclonal antibody. One skilled in the art knows how to select the framework protein. More particularly, it is known that, to be selected, such a framework must have several characteristics, such as the following (Skerra A., J. Mol.Recogn., 2000, 13, 167-187): a good phylogenetic conservation, a Robust architecture with a well-identified three-dimensional molecular organization (by crystallography or NMR, for example), small size, no or little post-translational modification (s), ease of production, expression and purification. Such a framework protein may be, but not limited to, a structure selected from the group consisting of fibronectin and, preferably, the tenth type III domain of fibronectin (FNfn10), lipocalin, anticalin (Skerra A., J. Biotechnol., 2001, 74 (4): 257-75), B domain-derived protein Z of staphylococcal protein A, thioredoxin A or any protein having a repeating domain such as ankyrin repetition "(Kohl et al., PNAS, 2003, 100 (4), 17001705), an" armadillo repeat ", a" leucine-rich repeat "or a" tetratricopeptide repeat ". One could also mention a framework derived from toxins (such as toxins from scorpions, insects, plants or molluscs, for example) or proteins inhibiting neuronal nitric oxide synthase (PIN). The following preparations and examples illustrate the invention but do not limit it in any way. General Procedures All reagents obtained from commercial sources were used without further purification. Anhydrous solvents were obtained from commercial sources and used without further drying. Flash chromatography was performed on an ISCO CombiFlash Rf 200i with pre-filled silica gel cartridges (RediSep®Rf Gold High Performance). Io Thin layer chromatography was performed with Merck Type 60 F254 silica gel coated 5 x 10 cm plates. Microwave heating was performed in an Anton Parr Mono Wave or CEM Discover0 instrument. Purifications by preparative HPLC were carried out on an Amen Spot liquid chromatography system with a 10 μM C18 Gemini-NX column, 250 mm × 50 mm, at a flow rate of 118 ml min-1 with UV detection by diode array. (210 nm to 400 nm) using an aqueous solution of 25 mM NH4HCO3 and MeCN as eluents unless otherwise indicated. Analytical LC-MS: The compounds of the present invention were characterized by high performance liquid chromatography-mass spectrometry (HPLC-MS) on an Agitate HP1200 with an Agilent 6140 quadrupole LC / MS, operating in either positive or negative mode. ionization by ionic electrospray. The scanning of the molecular weights ranges from 100 to 1350. A parallel UV detection was carried out at 210 nm and 254 nm. The samples were injected as a 1 mM solution in ACN 25 or THF / H20 (1/1) in a 5 cm loop. The LC-MS analyzes were performed on two instruments, one working with basic eluents and the other with acidic eluents. LC-MS basic: Gemini-NX column, 3 μm, C18, 50 mm X 3.00 mm d.i. at 23 ° C, at a flow rate of 1 ml min-1 using 5 mM ammonium bicarbonate (solvent A) and acetonitrile (solvent B) with a gradient starting with 100% solvent A and ending with 100% solvent B for a certain variable duration. AC-MS acid: ZORBAX column Eclipse XDB-C18, 1.8 μm, 50 mm X 4.6 mm d.i. at 40 ° C, at a flow rate of 1 ml min -1 using 0.02% v / v aqueous formic acid (solvent A) and 0.02% v / v formic acid in acetonitrile (solvent B) with a gradient starting with 100% solvent A and ending with 100% solvent B for a variable length of time. The 1H NMR measurements were performed on a 500 MHz Bruker Avance III spectrometer and a 400 MHz Braker Avance III spectrometer, using DMSO-d6 or CDCl3 as the solvent. The 1 H NMR data are in the form of delta values, given in part per million (ppm), obtained with respect to the residual peak of the solvent (2.50 ppm for DMSO-d6 and 7.26 ppm for CDCl3). taken as internal standard. The separation profiles are named: s (singlet), d (doublet), t (triplet), q (quadruplet), quint (quintuplet), m (multiplet), s large (singlet wide), dd (doublet of doublets) , td (triplet of doublets), dt (doublet of triplets), ddd (doublet of doublet of doublets). Gas chromatography and low resolution mass spectrometry in combination were performed on an Agilent 6850 gas chromatograph and an Agilent 5975C mass spectrometer using a 15 m × 0.25 mm column with a 0.25 coating. um HP-5MS and helium as carrier gas. Ionic source: EI +, 70 eV, 230 ° C, quadrupole: 150 ° C, interface: 300 ° C. The high resolution masses (HRMS) were determined on a Shimadzu IT-TOF, ionic source temperature of 200 ° C, ESI + 1-, ionization voltage: (+ -) 4.5 kV. Min. Mass resolution 10,000 elemental analyzes were performed on a Thermo Flash EA 1112 elemental analyzer.
[0012] List of Abbreviations Abbreviation Name Ac Acetyl AIBN 2 - [(1-cyano-1-methyl-ethyl-azazo] -2-methyl-propanenitrile AtaPhos bis (di-tert-butyl (4-dimethylaminophenyl) phosphine) dichloropalladium (II) DCM methylene chloride DIPA Diisopropylamine DMF dimethylformamide DMSO dimethylsulfoxide Equivalent and ethyl HMDS hexamethyldisilazane Prisopropyl Me methyl MeCN, ACN acetonitrile NBS N-bromosuccinimide Bu n-butyl Ph phenyl tBu tert-butyl tBuXPhos 2-di ( tert-butylphosphino) -21,42,6'-triisopropylbiphenyl TFA trifluoroacetic acid THF tetrahydrofuran General Procedure I: Step A 1 eq of the appropriate alcohol and 1.2 eq of pyridine were dissolved in methylene chloride ( 1.2 mmol) 1.05 eq of 1-chloroethyl chloroformate was slowly added at -78 ° C under nitrogen and the reaction mixture was stirred at -78 ° C for 3 hours The cold mixture was filtered and the filtrate was concentrated under The crude product was used without further purification.
[0013] Step B 1 eq. of Preparation 12, Preparation 13 or Preparation 14 was dissolved in DMF (20 ml / mmol) under nitrogen. 6.7 eq. of Cs2CO3 and 8 eq. 1-chloroethyl carbonate reagent were added. The reaction mixture was stirred at room temperature until no further conversion was observed. The mixture was diluted with brine and was extracted with DCM, dried with Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by reverse phase preparative chromatography using 5 mM aqueous NH4HCO3 and acetonitrile as eluents to obtain the appropriate carbonate derivative as a mixture of stereoisomers.
[0014] General Procedure II: Step A 1.05 eq. of amine reagent and 1.15 eq. of pyridine were dissolved in 1.3 ml / mmol of methylene chloride and then 1 eq. 1-chloroethyl chloroformate was added at-78 ° C under nitrogen. The reaction mixture was stirred at -78 ° C until no further conversion was observed. The cold mixture was filtered; the filtrate was concentrated under reduced pressure (30 mbar) using a bath at 30 ° C. The crude product was used within 3 hours without further purification.
[0015] Step B 1 eq. Preparation 12, Preparation 13 or Preparation 14 was dissolved in 20 ml / mmol DMF under nitrogen. 10 eq. of Cs2CO3, then 8 eq. Carbamate reagent (0.8 M solution of crude product from Step A in DMF) was added. The reaction mixture was stirred at room temperature until no further conversion was obtained. The mixture was diluted with brine and was extracted several times with ethyl acetate. The combined organic layer was dried over MgSO4, filtered and concentrated under reduced pressure and purified by reverse phase preparative chromatography using 5 mM aqueous NH4HCO3 solution and acetonitrile as eluents to obtain the carbamate derivative.
[0016] Preparation 1: 5-Bromo-4-chloro-6-iodo-thieno [2,3-d] pyrimidine Step A: 6-Iodo-3H-thieno [2,3-d] pyrimidin-4-one One flask 2 L round bottom equipped with a mechanical stirrer, a thermometer and a reflux condenser was charged with a solution containing 433 ml of acetic acid, 13 ml of sulfuric acid and 87 ml of water. . 69.3 g of 3H-thieno [2,3-d] pyrimidin-4-one (0.46 mol), 51.9 g of periodic acid (0.23 mol) and 104 g of iodine (0.41 g) mol) were added to the stirred solution, which was heated at 60 ° C for 1 hour. The resulting suspension was cooled to room temperature, filtered, washed with a mixture of acetic acid and water (5: 1), and then with diethyl ether. The resulting beige crystalline solid was air dried. 1 H NMR (500 MHz, DMSO-d 6): 12.57 (bs, 1H), 8.09 (s, 1H), 7.65 (s, 1H). Step B: 4-Chlaro-6-iodothiotho [2,3-d] pyrimicline A 1 L round bottom flask equipped with a mechanical stirrer, thermometer, reflux condenser and CaCl 2 tube was charged with 113 ml of oxychloride Phosphorus and 35 ml of N, N-dimethylaniline (0.29 mol). 75.54 g of 6-iodo-3H-thieno [2,3-d] pyrimidin-4-one (0.27 mol) was added to the mixture in portions over a period of 5 minutes. The reaction mixture was stirred at 105 ° C for 1 hour. The resulting slurry was cooled to 10 ° C, filtered and washed with hexane. The crude product was added to ice water and stirred for 10 minutes, removed by filtration, washed with cold water, diethyl ether and air-dried. A beige crystalline solid was obtained. 1H NMR (400MHz, DMSO-d 6): 8.89 (s, 1H), 7.98 (s, 1H). Step C: 5-Bromo-4-chloro-6-iodothieno [2,3-d] d] Pyrimidine A 2 L round bottom flask equipped with a mechanical stirrer, thermometer and bubbler was charged with 600 ml of acetonitrile. 84.9 g of 4-chloro-6-iodothieno [2,3-d] pyrimidine (0.29 mol), 50.9 g of NBS (0.29 mol) and 8.5 mL of tetra acid complex Fluoroboric / diethyl ether was added. The reaction mixture was stirred at room temperature for 16 hours. An additional 22.9 g (0.12 mol) of NBS was added to the mixture in three portions. After cooling the suspension to 0 ° C and stirring for a further 1 hour, the precipitate was removed by filtration, washed with acetonitrile and air-dried. Preparation 1 was obtained as a crystalline beige solid. NMR11 (500 MHz, DMSO-d6): 8.88 (s, 1H) Preparation 2: 5-Bromo-4-chloro-6- (4-fluorophenyl) thieno [2,3-dipyrimidine 75.08 g of Preparation 1 (200 mmol), 53.63 g of 2- (4-fluorophenyl) -4,4,5,5-tetramethyl-1,3,2-dioxaborolane (240 mmol), 130 g of cesium carbonate (400 mmol 2.245 g Pd (OAc) 2 (10 mmol) and 8.50 g tBuX-Phos (20 mmol) were placed in a 2 L flask. 600 ml THF and 200 ml Water was added, and then stirred overnight at 70 ° C under an argon atmosphere. THF was evaporated, and the product was collected by filtration. The crude product was sonicated in 250 ml of acetonitrile and filtered again. Then, Preparation 2 was crystallized from EtOH / THF (2: 1).
[0017] NMR (400 MHz, DMSO-d6): 9.02 (s, 1H), 7.80-7.77 (m, 2H), 7.47-7.43 (n, 2H) Preparation 3: (2R) Ethyl 2-acetoxy-3- (2-hydroxyphenyl) propanoate Step A: 12- (Bromomethyl) phenylacetate 60.07 g of 2-methylphenyl acetate (400 mmol) and 106.8 g of NBS ( 600 mmol) were placed in a 1 L flask. 500 mL of cyclohexane was added, and then with intensive stirring, 3.284 g of AIBN (20 mmol) was added over 30 minutes. The mixture was stirred at 80 ° C until no further conversion was observed and then cooled to room temperature. The precipitate was removed by filtration and washed with cyclohexane.
[0018] The mother liquor was concentrated under reduced pressure, and the crude product was used in step B without further purification. Step B: Ethyl (2R) -2-acetoxy-3- (2-hydroxyphenyl) propanoate 23.10 g of anhydrous LiCl (545 mmol) and 65.36 g of anhydrous ZnCl 2 (479.6 mmol) were added. placed in a 2 L flask, then dried at 160 ° C under 0.1 mmHg for 1 hour. After cooling to room temperature under an argon atmosphere, 26.49 g of magnesium turnings (1090 mmol) and 1 L of pre-cooled dry THF (0 ° C) were added. The resulting mixture was immersed in an ice bath, and then stirred for 30 minutes. 100 g of [2- (bromomethyl) phenyl] acetate crude product from step A (436 mmol) was dissolved in 120 mL of dry THF and added to pre-cooled inorganic components over 15 minutes. After addition of the reagent, the resulting mixture was stirred for 45 minutes while maintaining the temperature between 0 and 5 ° C. To the mixture was added 64.82 mL of ethyl 2-oxoacetate (654 mmol, 50% in toluene) over 5 minutes and the resulting mixture was stirred for another 15 minutes. The remaining inorganic components were removed by filtration, and then 500 mL of MeOH was added to the filtrate. This mixture was stirred until the migration of the intramolecular acetyl group from phenolic oxygen to alkyl oxygen was complete. 30 ml of acetic acid were added to the mixture and the volatiles were then evaporated under reduced pressure. To the residue, 350 mL of water was added and extracted with EtOAc. The combined organic layers were washed with saturated NaHCO3 and brine, and then dried over MgSO4, filtered and evaporated under reduced pressure. To the residue, 100 mL of hexane was added and stirred for 30 minutes at 0 ° C. The formed white crystals were collected by filtration and washed with hexane to give enantiomers which were separated by chiral chromatography. Column: OD; Eluents: heptane / EtOH; the (S) -enantiomer at earlier elution was collected with 99.8% ee and the later-eluting (R) -enantiomer was collected as Preparation 3 with 99.9% ee. 1H NMR (500 MHz, DMSO-d6) δ 9.53 (s, 1H), 7.06 (t, 1H), 7.04 (d, 1H), 6.79 (d, 1H), 6.71. (t, 1H), 5.10 (dd, 1H), 4.05 (q, 2H), 3.06 (dd, 114), 2.94 (dd, 1H), 2.00 (s, 3H) 1.09 (t, 3H) Preparation 4: Ethyl (2R) -2-hydroxy-3- (2-tetrahydropyran-2-yloxyphenyl) propanoate Step A: (2R) -2-Acetoxy-3- ( Ethyl 2-tetrahydropyran-2-yloxyphenyl) propanoate 103.3 g of Preparation 3 (409 mmol) was dissolved in 280 mL of 3,4-dihydro-2H-pyran. 300 mg of para-toluenesulfonic acid monohydrate was added and the mixture was stirred until no further conversion was observed. It was then diluted with 1 L of ethyl acetate, washed with 200 mL of saturated NaHCO3 solution and then with 200 mL of water. The combined organic layers were dried over Na2SO4, filtered and concentrated. Then, the mixture was purified by flash chromatography using heptane / EtOAc. Ethyl (2R) -1- (2R) -2-hydroxy-3- (2-tetrahydropyran-2-yloxyphenyl) propionate 137.57 g of (2R) -2-acetoxy-3- (2-tetrahydropyran-2-yloxyphenyl) propionate The ethyl acetate (409 mmol) was dissolved in 600 mL of ethanol, then 20 mL of a solution of sodium ethoxide (1M in ethanol) was added and the mixture was stirred until no further conversion was observed The mixture was concentrated to half its volume, then 300 ml of water and 300 ml of brine were added, and it was extracted with water. The combined organic components were dried over sodium sulfate, filtered, and concentrated.The enantiopurity of the starting material was maintained: 111 NMR (500 MHz, DMSO-d6, 1: 1 mixture). diastereomers S 7.16 (t, 1H), 7.13 (d, 1H), 7.04 (d, 1H), 6.87 (t, 1H), 5.51-5.47 (m, 1H) ), 4.27 (m, 1H), 4.04-4.02 (q, 2H), 3.73-3.56 (m, 2H), 3.06-3.04-2.74-2 , 71 (dd, 2H), 1.95-1.64 (m, 2H), 1.79 (m, 2H), 1.651.50 (m, 211), 1.12-1.10 (t, 3H) Preparation 5: (2R) -2-15-Bromo-6- (4-fluorophenyl) thieno [2] Ethyl 3-di-pyrimidin-4-yl] oxy-3 (2-tetrahydropyran-2-yloxyphenyl) propanoate 48.45 g Preparation 2 (141 mmol), 45.63 g Preparation 4 (155 mmol) and 137.8 g of Cs2CO3 (423 mmol) were placed in a 2 L flask. 1.4 L of tert-butanol was added and the mixture was stirred at 70 ° C under N 2 until no other conversion is observed. About 1 L of solvent was evaporated under reduced pressure, then it was diluted with water, the pH was adjusted to 8 with 2M HCl, and then it was extracted with DCM. The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using heptane and EtOAc as eluents to obtain Preparation 5 as a mixture of diastereoisomers.
[0019] 111 NMR (500 MHz, DMSO-d6): 8.67-8.66 (s, 1H), 7.75 (m, 2H), 7.43 (dm, 1H), 7.41 (m, 2H); ), 7.19 (in, 1H), 7.08-7.06 (dm, 1H), 6.89 (in, 1H), 5.87-5.70 (dd, 1H), 5.605.55 ( m, 1H), 4.23-4.08 (m, 2H), 3.80-3.48 (in, 2H), 3.52-3.49 (dd, 1H), 3.19-3, 17 (dd, 1H), 2.09-1.49 (m, 6H), 1.15-1.10 (t, 3H) High resolution (HRMS) mass calculated for C281-126BrFN2O5S: 600.0730, 25 found. 601.0809 / 601.0798 (M + H) Preparation 6: phenol 2-Chloro-3-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) Step A: (4-Bromo-2-chloro-pherroxy) -trimethylsilane 20.8 g of 4-bromo-2-chlorophenol (100 mmol) was dissolved in 150 ml of dry TE followed by 24 2 g of HMDS (150 mmol) was added. The reaction mixture was stirred at 85 ° C under argon for 1.5 hours and then concentrated under reduced pressure to give the product used without further purification. 1H NMR (200 MHz, CDCl3): 7.49 (d, 111), 7.23 (dd, 1H), 6.75 (d, 1H), 0.26 (s, 9H) Step B 4-Bromo -2-chloro-3-methylphenol 48 ml of a solution of nBuLi in hexanes (2.5 M, 120 mmol) was added dropwise to a solution of 12.1 g of dry DIPA ( 120 mmol) in 250 mL of dry THF at -78 ° C under argon atmosphere. The mixture was stirred for 30 minutes at the same temperature, then 28.0 g of (4-bromo-2-chloro-phenoxy) -trimethylsilane (100 mmol) was added dropwise. After 2.5 hours, 21.3 g of MeI (150 mmol) was added dropwise, then the cooling bath was removed and the mixture was stirred overnight. The reaction was quenched with 100 ml of NH4OH solution and 200 ml of NH4Cl solution and extracted with EtOAc, dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting black mass was refluxed in pure hexane several times (150 ml aliquots to 150 ml) and decanted to leave a black tar. The combined organic phases were concentrated under reduced pressure to give 19.0 g of crude product used without further purification. 111 NMR (200 MHz, CDCl3): 7.32 (d, 1H), 6.76 (d, 1H), 5.62 (s, 1H), 2.49 (s, 3H) Step C: (4H NMR (CDCl3) 3-Bromo-2-chloro-3-methyl -Phenol (86.0 mmol) in 150 ml of dry THF. The mixture was stirred at 85 ° C. under argon in a flask for 1.5 hours and then concentrated under reduced pressure. The product obtained was used without further purification. NMR 111 (200 MHz, CDCl3): 7.30 (d, 1H), 6.63 (d, 1H), 2.50 (s, 3H), 0.28 (s, 9H). Step D: 2-Chloro 3-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenol A solution containing 25.2 g of (4-bromo-2-chloro-3- Methyl-phenoxy) -trimethylsilane (86.0 mmol) in 250 ml of dry THF was cooled to -78 ° C under argon and then 38 ml of nBuLi in hexanes (2.5M, 94.6%) were added. mmol) were added dropwise. After 5 minutes, 19.2 g of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (103 mmol) was added dropwise. The cooling bath was removed and the mixture was allowed to warm slowly to room temperature. Then, the mixture was added to 200 μl of NH4Cl solution and extracted with EtOAe. The combined organic layers were concentrated under reduced pressure and passed through a pad of silica gel using hexane and EtOAc as eluents. The crude product was recrystallized from a mixture of EtOAc and hexane to obtain Preparation 6. 1H NMR (500 MHz, DMSO-d6): 10.40 (s, 1H), 7.42 (d, 1H) , 6.80 (cl, 1H), 2.49 (s, 3H), 1.27 (s, 12H).
[0020] Preparation 7: (2R) -2-1 (5S ') - 5- (3-chloro-4-hydroxy-2-methyl-phenyl) -6- (4-fluorophenyl) thieno [2,3-d] pyrimidin Ethyl 4-yloxy-3- (2-tetrahydropyran-2-yloxyphenyl) propanoate 186.6 g of Preparation 5 (310.3 mmol) and 99.99 g of Preparation 6 (372.3 mmol) were added. dissolved in 1.2 L of THF, then 202.2 g of Cs2CO3 (620.6 mmol) dissolved in 300 mL of water was added. Then, 11.0 g of AtaPhos (15.51 mmol) was added and the mixture was stirred under nitrogen at reflux temperature until no further conversion was observed. Most volatiles were evaporated under reduced pressure and then the reaction was diluted with methylene chloride and brine. After stirring, the pH of the aqueous phase was adjusted to 8 with 2M HCl.
[0021] After phase separation, the aqueous phase was extracted with methylene chloride. The organic layers were combined and dried over Na2SO4, filtered and concentrated under reduced pressure. The diastereoisomers were separated by flash chromatography using heptane and ethyl acetate as eluents. The late-eluting diastereoisomer pair was collected as Preparation 7.
[0022] NMR III (500 MHz, DMSO-d6, 1: 1 mixture of diastereomers): 10.27 (bs, 1H), 8.60 (s, 1H), 7.30 (m, 2H), 7.22. (m, 2H), 7.16-7.14 (d, 1H), 7.12 (in, 1H), 7.00 (d, 1H), 6.96 (d, 1H), 6.74- 6.73 (t, 1H), 6.34-6.36 (d, 1H), 5.55-5.52 (m, 1H), 5.54-5.41 (dd, 1H), 4, 06 (q, 211), 3.68-3.54 (in, 214), 3.10-3.07 (dd, 1H), 2.44 (dd, 1H), 1.98-1.90 ( broad, 1H), 1.85-1.83 (s, 3H), 1.79 (bs, 2H), 1.64 (bs, 1H), 1.59 (bs, 1H), 1 , 54 (bs wide, 1H), 1.09-1.08 (t, 3H) High resolution mass (HRMS) (M + 11) = 663, 1728 and 663, 1717 Preparation: (2R) 2 - [(5Sa) -5- [13-ethyl] -4- [2- (4-methylpiperazin-1-yl) ethoxy] phenyl] -6- (4-fluorophenyl) thieno [2,3-diol]; Ethyl pyrimidin-4-yl] oxy-3- (2-tetrahydropyran-2-yloxyphenyl) propanoate 132.3 g of Preparation 7 (199.5 mmol), 43.17 g of 2- (4-Methylpiperazin-1-yl) ethanol (299.3 mmol) and 94.20 g of PPh 3 (359.1 mmol) were dissolved in 1 L of dry toluene and then 78.09 g of di-tert- butyl azodica Rboxylate (339.2 mmol) was added. The mixture was stirred at 50 ° C under N 2 until no further conversion was observed. 980 mL of toluene was evaporated, then 500 mL of Et 2 O was added, and the mixture was stirred and sonicated. The precipitated white crystals were filtered, washed with Et2O to give 65.9 g of pure triphenylphosphineoxide. The filtrate was concentrated under reduced pressure and purified by flash chromatography using EtOAc and MeOH as eluents to obtain Preparation 8. MS: (M-FH) + = 789.2 Preparation 9: (2R) -2 - [(5Sa) 43-chloro-2-methyl-442- (4-methylpipoxyethoxy) phenyl-6- (4-fluorophenyl) thieno [2,341 pyrimidoxy-3- (2-hydroxyphenyl) propanoate] 199.5 mmol of Preparation 8 were dissolved in 1 L of EtOH, then 1 L of 1.25M HCl in EtOEI was added and the mixture was stirred at room temperature until the reaction was complete. no further conversion was observed Most of the EtOH was evaporated, then Et 2 O was added and the precipitated HCl salt (white solid) was filtered, washed with The HCl salt was carefully treated with saturated NaHCO 3 solution, extracted with DCM, the combined organic phases were dried over Na 2 SO 4, filtered and concentrated under reduced pressure to give Preparation 1: 1 H NMR (400 MHz, DMSO-d 6): 9.53 (br s, 1H), 8.60 (s, 1H), 7.30 (m, 2H), 7.28 (d, 1H), 7.21 (m, 2H), 7.16 (d, 1H), 6.97 (t, 1H), 6.72 (d, 11-1), 6.53 (t, 1H), 6.20 (d, 1H), 5.46 (dd, 1H), 4.22 (m, 2H), 4.04 (m, 2H), 2.92 (dd, 1H), 2.75 (m.p. , 2H), 2.53 (bs, 4H), 2.44 (dd, 1H), 2.36 (bs, 4H), 2.17 (s, 3H), 1.88 (s, 3H). 1.06 (t, 3H) High resolution mass (HRMS) calculated for C 371-138CIFN 4 O 5 S: 704.2235, found: 705.2288 (M + H) Preparation 10: (E) -4- ( 1,1-dimethoxypropan-2-one (4.25 mol) and 506.4 g V, N-dimethyl-methanamine (4.25 mol) was mixed in a 2 L flask and stirred at 105 ° C for 3 hours. The formed MeOH was continuously removed by distillation. When the formation of MeOH stopped (at a head temperature of 65 ° C), the reaction mixture was distilled under vacuum (slowly decreasing the pressure to 30 mbar) to remove side products and compounds. departure not having reacted. The crude product was distilled at 0.1 mbar. Fractions were collected at a head temperature between 107 ° C and 118 ° C (bath temperature 160 ° C to 165 ° C) to give a yellow oil. 1 H NMR (500 MHz, DMSO-d6): 7.59 (d, 1H), 5.17 (d, 1H), 4.42 (s, 1H), 3.25 (s, 6H), 3.09 (b.p. s, 3H), 2.78 (s, 3H) Preparation 11: [2- (2-Methoxyphenyl) pyrimidin-4-311methanol Step A: 4- (Dimethyloxymethyl) -2- (2-methoxyphenyl) pyrimidine Au mixture of 2-methoxybenzamidine hydrochloride (1.2 eq.) and Preparation 10 (1 eq.) in dry methanol (0.5 mL / mmol) was added sodium methoxide (1.2 eq. ) in portions and the mixture was stirred at 75 ° C for 2 hours. The reaction mixture was cooled and concentrated under reduced pressure. To the residue, water was added and extracted with DCM. The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using heptane and EtOAc as eluents. NMR (400 MHz, DMSO-d6): 8.93 (d, 1H), 7.55-7.44 (in, 3H), 7.16 (d, 1H), 7.06 (m, 1H), 5.31 (s, 1H), 3.76 (s, 3H), 3.37 (s, 6H) Step B 261 mg of 4- (dimethoxymethyl) -2- (2-methoxyphenyl) -pyrimidine (1, 00 mmol) were dissolved in 2 ml of HCl in dioxane (4M solution), then 2 ml of water was added and this mixture was stirred at 50 ° C for 16 hours. The reaction mixture was cooled to 0 ° C and then 320 mg NaOH (8.0 mmol) was added portionwise. The pH was adjusted to 8 using a 10% K2CO3 solution, then 76 mg of sodium borohydride (2.0 mmol) was added and the mixture was stirred for 30 minutes at 0 ° C. The reaction mixture was diluted with 5 ml of water and extracted with EtOAc. The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography using heptane and EtOAc as eluents to give Preparation 11. 1H NMR (400 MHz, DMSO-d6): 8.84 (d, 1H) , 7.50-7.42 (m, 3H), 7.14 (d, 1H), 7.03 (In, 1H), 5.66 (t, 1H), 4.58 (d, 2H), 3.75 (s, 3H) Preparation 12: (2R) -2-1 [(54-5- (3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl) - 6- (4-fluorophenyl) thieno [2,3-Mpyrimidin-4-yl] oxy} -3- (2-yl- (2-methoxyphenyl) pyrimidin-4-amethoxy) phenyl) propanoic acid Step A 1 eq. Preparation 9, 2 eq. Preparation 11 and 2 eq. triphenyl phosphine were dissolved in toluene abs. (0.2M for phenol), then 2 eq. di-tert-butyl azodicarboxylate was added. The mixture was stirred at 50 ° C under nitrogen until no further conversion was observed. Volatiles were evaporated under reduced pressure and the crude intermediate was purified by flash chromatography using ethyl acetate and methanol as eluents. Step B The resulting intermediate was dissolved in dioxane-water 1: 1 (10 mL / mmol) and 10 eq. LiOH x 1120 were added. The mixture was stirred at room temperature until no further conversion was observed. Then it was diluted with brine, neutralized with 12M HCl, extracted with methylene chloride. The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure and purified by reverse phase preparative chromatography using 25mM aqueous N1-141-1CO3 and MeCN as eluents. HRMS calc for C47H44ClFN606S: 874.2716; found 438.1415 (M + 2H) Preparation 13: (2R) -2-1 [543,5-Dichloro-2,6-dimethyl-4- (4-methylpiperazin-1-yl) ethoxylphenyl) - 6- (4-Finorophenyl) thieno [2,3-a] pyrimidin-4-yloxy) -3- (2 - {[2- (2-methoxyphenyl) pyrimidin-4-yl] methoxy} phenyl) propanoic acid 3037957 -37 Preparation 14: (2R) -24 [5-12,6-dimethyl-4- [4- (4-methylpiperazin-1-yl) -ethoxy] phenyl] -6- (4-fluorophenyl) thieno [2,3-d] ] pyrimidin-4-yloxy} -3- (2- (12- (2-methoxyphenyl) pyrimidin-4-ylmethoxy} phenyl) propanoic acid Example 1: (2R) -2- ([(5S ') - 5- [ 2,3-d] pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) pyrimidin-4-ylmethyloxy} phenyl) propanoyl) 1- [(m ethoxycarbonyl) oxy] ethyl Following General Procedure I and taking Preparation 12 and methanol as the appropriate alcohol, Example 1 was obtained High resolution mass (HRMS) calculated for C 51 H 50 ClFN 609 S: 976,3033, found 489,1604 and 489,1572 (M + 2H) Example 2: (2R) -2- {[(5S ') - 5- {3-chloro-2-methyl) 4- [2- (4-methylpiperazin-1-yl) oxy] -phenyl] -6- (4-fluorophenylthieno [2,3-d] pyrimidoxy] -3- [2,42]; Methylphenyl) pyrimidin-4-yl] methoxyphenyl) propanoate 1 - [(ethoxycarbonyl) oxy] ethyl Following General Procedure I and taking Preparation 12 and ethanol as the appropriate alcohol, Example 2 was obtained. High resolution mass (HRMS) calculated for C52H52ClFN609S: 990.3189; found 496, 1649, and 496, 1685 (M + 21-1). Example 3: (2R) -2 - {[(5S ') - 5- (3-chloro-2-methyl-4-12-) -4- methylpiperazin-1-yl) ethoxyl- (phenyl) -6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4 (12- (2-methoxyphenyl) pyrimidin-4-ylmethoxy} phenyl) 1- {[(prop-n-2-yloxy) -carbonyl] oxy} ethyl propanoate Following General Procedure I and taking Preparation 12 and 2-propanol as the appropriate alcohol, Example 3 was obtained. . High resolution mass (HRMS) calculated for C531154CIFN609S: 1004.3345; found 503.1766 (M + 2H) Example 4: (2R) -2- (K5S ') - 5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxylphenyl} 6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yl] oxy} -3- (2-1 [2- (2-methoxyphenyl) pyrimidin-4-ylmethoxy} phenyl) propanoate 11 (tert-Butoxycarbonyl) oxy] ethyl Following General Procedure I and taking Preparation 12 and 2-methyl-2-propanol as the appropriate alcohol, Example 4 was obtained. High resolution mass (HRMS) calculated for C54H56ClFN6O9S: 1018.3502; found 510.1837 (M + 21-1) Example 5: (2R) -2- (1 (5S ') - 5- (3-Ehlo) -2-methyl-4- [244-methylpiperazin-1- y1) ethoxy] phenyl) -6- (4-fluorophenyl) thieno [2,3-dipyrimidin-4-yl] oxy) -3- (2- {12- (2-methoxyphenyl) primidin-4-ylimethoxy) phenyl} 1- (1-Eyelopentyloxy) carbonyl-oxylethyl propanoate Following General Procedure I and taking Preparation 12 and cyclopentanol as the appropriate alcohol, Example 5 was obtained High resolution mass (HRMS) calculated for C55H56ClFN609S 1030.3502, found 516.1817 (M + 2H) Example 6: (2R) -2 - [(5Sa) -5- (3-chloro-2-methyl-442- (4-methylpiperazin) -1- y1) ethoxy-phenyl} -6- (4-fluoro-phenyl) -thieno [2,3-d] pyrimidin-4-yl-oxy-3- (2 (2-methoxyphenyl) pyrimidin-4 1- [1 (oetyloxy) -carbonyloxy) ethyl -methylphenyl) propanoate Following General Procedure I and taking Preparation 12 and 1-octanol as the appropriate alcohol, Example 6 was obtained. H RMS) calcd for C 58 H 64 ClF N 609 S: 1030.3502; found 538.2133 and 538.2149 (M + 2H) Example 7: (2R) -2 - {[(5S ') - 5- (3-Chloro-2-methyl-4- [2- (4-methylpiperazine 1-yl) ethoxy] phenyl-6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yl) oxy} -3- (2 - {[2- (2-methoxyphenyl) pyrimidin) 1 - [(dimethylamino)] oxy] ethyl 4-ylimethoxy) phenyl) propanoate Following General Procedure II and taking Preparation 12 and dimethylamine hydrochloride as the amine reagent and applying 2.15 eq. of pyridine in step A, Example 7 was obtained. High resolution mass (HRMS) calculated for C52H53ClFN7O8S: 989.3349; found 495.6740 and 495.6738 (M + 2H) Example 8: (2R) -2- (k5S) -5- {3-chloro-2-methyl-4-12- (4-methylpiperazin) -1- ypethoxy phenyl) -6- (4-fluorophenyl) thieno [2,3-dlpyrimidin-4-yl] oxy) -3- (2-1 [2- (2-methoxy-3-phenyl) pyrimidin-4- 1- (Diethylcarbamoyl) oxylethyl (methoxylphenyl) propanoate Following General Procedure II and taking Preparation 12 and diethylainine as the amine reactant, Example 8 was obtained. High resolution mass (HRMS) calculated for C54H57ClFN708S: 1017.3662; found 509.6902 (M + 2H) Example 9: 1-11 (2R) -2-1 [(5S ') - 5- {3-chloro-2-methyl-4- [2- (2-methyl) -4-morpholine-4-carboxylate) (4-methylpiperazin-1-yl) ethoxy] phenyl) -6- (4-fluoro-phenyl) thieno [2,3-d] pyrimidin-4-yloxy-3 - (2-1 [2- (2-methoxyphenyl)) Pyrimidin-4-yl] methoxyphenyl) propanoyl] oxylethyl Following General Procedure II and taking Preparation 12 and morpholine as the amine reactant, Example 9 was obtained. High resolution mass (HRMS) calculated for C541-155CIFN709S: 1031.3455; Found 516.6826 and 516.6821 (M + 2H) Example 10: (2R) -2 - [[(5Sa) -543-chloro-2-methyl-442- (4-methylpiperazin-1-yl) -ethoxylphenyl] 1 - ([(4-fluorophenyl) thieno [2,3-dlpyrimidin-4-yl] oxy} -3- (2- {12- (2-methoxyphenyl) pyrimidin-4-ylmethoxylphenyl) propanoate 2-methoxyethyl) carbamoyl] oxylethyl Following General Procedure II and taking Preparation 12 and 2-methoxyethanamine as the amine reagent, Example 10 was obtained High resolution mass (HRMS) calculated for C53H55ClFN7O9S: 1019, 3455, found 510.6809 and 510.6813 (M + 2H) Example 11: (2R) -2 - {[(54-5- {3-chloro-2-methyl-442- (4-methylpiperazin-1) Y1) -Ethoxylphenyl} -6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yl] oxy} -3- (2- {12- (2-methoxyphenyl) pyrimidin-4-ylmethoxy} 1 - {[bis (2-methoxyethyl) carbamoyl] oxy} ethyl phenol) propanoate Following General Procedure II and taking Preparation 12 and 2-methoxy-N- (2-methoxyethyl) ethanamine co same amine reagent, Example 11 was obtained High resolution mass (HRMS) calculated for C 56 H 61 ClFN 70 O 20: 1077.3873; found 539.7029 and 539.7017 (M + 211) Example 12: (2R) -2- (R5S ') - 5- (3-chloro-2-methyl-4- [2- (4- methylpiperazin-1-yl) -ethoxy] phenyl-6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yloxy) -3- (2- [242] 1 - {[(2-methoxy-2-oxoethyl) (methyl) carbamoyl] oxy} ethyl) ethoxy-phenylmethyl-4-yl] -methoxy-phenylpropanoate following general procedure II and taking Preparation 12 and methyl 2- (methylamino) acetate hydrochloride as the amine reagent and applying 2.15 eq of pyridine in Step A, Example 12 was obtained High resolution mass (HRMS) calculated for C54H55ClFN7O10S: 1047.3403, found 524.6782 and 524.6781 (M + 2I-I) Example 13: (2R) -2- - [[(5S,) - 5- {3-chloro-2-methyl) 4- [2- (4-methylpiperazin-1-yl) ethoxy] phenyl] -6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yloxy} -3- (2- {[ Phosphonooxy-methyl 2- (2-methoxyphenyl) pyrimidin-4-yl] methoxyphenyl) propanoate 700 mg Prepared 12 (0.8 mmol), 233 mg of di-tert-butyl aluminaphosphate (0.9 mmol), 240 mg of sodium iodide (1.6 mmol) and 521 mg of Cs2CO3 (1.6 mmol). ) were dissolved in 8 mL of DMF and the reaction mixture was stirred at room temperature under a nitrogen atmosphere until no further conversion was observed. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water, dried over Na 2 SO 4 and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel using DCM and MeOH as eluents to obtain the di-tert-butyl ester intermediate. 160 mg of di-tert-butyl ester (0.15 mmol) was dissolved in 8 mL of DCM and cooled in an ice-water bath. 4 mL of TFA was slowly added to the mixture. After addition of TFA, the mixture was stirred for an additional 15 minutes and then concentrated under reduced pressure to obtain the crude product as salt. Preparative HPLC using formic acid solution and ACN followed by lyophilization gave Example 13 as a white solid. High resolution mass (HRMS) calculated for C481-147CIFN6010PS: 984.2485; found 493.1388 (M + 2H) Example 14: (2R) -2- (15- {2,6-dimethyl-442- (4-methylpiperazin-1-yl) ethoxylphenyl} -6- 1-Kethoxyearbonyl) oxylethyl (fluorophenyl) thieno [2,3-d] pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-ylmethoxy} phenyl) propanoate Following General Procedure I and taking Preparation 14 and ethanol as the appropriate alcohol, Example 14 was obtained. Example 15: (2R) -2- {15- {3,5-Dichloro-2,6-dimethyl-442- (4-methylpiperazin-1-yl) -ethoxyl phenyl} -6- (4-fluorophenyl) thieno [ 2,3 - [1 - [(Ethoxyearbonyl)) oxy] -2- (2 - {[2- (2-methoxyphenyl) pyrimidin-4-yl] methoxy} phenyl) propanoate 2,3-pyridin-4-yloxy-oxy] Following general procedure I and taking Preparation 13 and ethanol as the appropriate alcohol, Example 15 was obtained.
[0023] Example 16: (2R) -2-115- (2,6-Dimethyl) -4- [2- (4-methylpiperazin-1-yl) ethoxy] phenyl} -6- (4-fluorophenyl) thieno [2,3-di-pyrimidin-4-yl] oxy} -3- (2- [2- [2- (2-methoxyphenyl) -pyrimidin-4-yl) ethoxy] phenyl) propaneate of 1 - [( The reaction is carried out in accordance with general procedure II and taking Preparation 14 and dimethylamine hydrochloride as the amine reactant and applying 2.15 eq. of pyridine in Step A, Example 16 was obtained. Example 17: (2R) -2 - ([5-13,5-dichloro-2,6-dimethyl-4-12- (4-methylpiperazin-1-yl) -ethoxyphenyl] -6- (4-fluoropyronyl) 1-E (dimethylcarbamoyl) ethoxylated ethyl (2,3-d] pyrimidin-4-yl] oxy) -3,4 [[2-methoxyphenyl) pyrimidin-4-yl] methoxylphenyl) propanoate following general procedure II and taking Preparation 13 and dimethylamine hydrochloride as the amine reagent and applying 2.15 eq of pyridine in Step A, Example 17 was obtained. EXAMPLE A: Inhibition of Mc1-1 by the Fluorescence Polarization Technique The relative binding activity of each compound was determined by fluorescence polarization (PF) The method employs a fluorescein-labeled ligand (fluorescein). PAla-Ahx-A-REIGAQLRRMADDLNAQY-OH; pm 2,765) which binds to the Mc1-1 protein (such as Mc1-1 corresponding to the UniProtKB® primary accession number: Q07820), resulting in a anisotropy measured in milli-polarization unit (mP) by means of a reader. The addition of a compound that competitively binds to the same site as the ligand will lead to an increase in the proportion of unbound ligand in the system, indicated by a decrease in mP units. An 11-point serial dilution of each compound was prepared in DMSO and 2 111 were transferred to a 384-well flat-bottomed, low-binding plate (5% final DMSO concentration). 38 μl of buffer (10 mM 4- (2-hydroxyethyl) -1-piperazinethanesulfonic acid [HEPES], 150 mM NaCl, 0.05% Tween 20, pH 7.4) containing fluorescein-labeled ligand (final concentration of 1 nM) and Mc1-1 protein (final concentration of 5 nM) were then added. Assay plates were incubated for about 2 hours at room temperature before measuring FP with a Biomek Synergy2 reader (eg, 528 min, Em 640 min, 510 nm cut-off), and calculated. mP units. The binding of increasing doses of test compound was expressed as percent reduction in mP from a window set between a control group representing "5% DMSO only" and a control group representing "100% inhibition". The 11-point dose / response curves were plotted with the XL-Fit software using a 4 parameter logistic model (sigmoid dose / response model) and the inhibitory concentrations giving a 50% reduction in mP (IC50 ) have been determined. The results are shown in Table 1 below. The results show that the compounds of the invention inhibit the interaction between the Mc1-1 protein and the fluorescent peptide described above. EXAMPLE B Cytotoxicity In Vitro Cytotoxicity studies were performed on the 11929 multiple myeloma tumor line. The cells are plated in microplates and exposed to the test compounds for 48 hours. Cell viability is then quantified by a colorimetric assay, Microculture Tetrazolium Assay (Cancer Res., 1987, 47, 939-942). The results are expressed as 1050 (compound concentration which 50% inhibits cell viability) and are shown in Table 1 below. The results show that the compounds of the invention are cytotoxic.
[0024] Table 1: Mei-1 Inhibition (Fluorescence Polarization Test) and Cytotoxicity for H929 IC50 (IlM) 1050 (11M) IC50 (1.1M) 1050 (FtM) i Mc1-1 FP Mil 11929 Mc1-1 FP Mn-11929 Example 1 0.037 ND Example 11 0.551 ND Example 2 0.361 ND Example 12 0.318 ND Example 3 0.292 ND Example 13 0.0032 ND Example 4 0.959 ND Example 14 ND ND Example 5 0.37 ND Example EXAMPLE 6 0.51 ND EXAMPLE 16 ND EX EXAMPLE 7 0.438 ND Example J17 ND ND Example 8 1.41 ND Example 9 0.52 ND Preparation 13 ND ND Example 10 0.147 ND Preparation 14 ND ND ND: Not determined 15 EXAMPLE C Quantification of the cleaved form of PARP in vivo The ability of the compounds of the invention to induce apoptosis, by measuring cleaved PARP levels, is evaluated in a multiple myeloma cell xenograft model AMO-1 . 1.107 AMO-1 cells are grafted under the skin of immunocompromised mice (strain SCID). 12 to 14 days after the transplant, the animals are treated intravenously or orally with the various compounds. After treatment, the tumor masses are removed and lysed, and the cleaved form of PARP is quantified in the tumor lysates. Quantification is performed using the Meso Scale Discovery (MSD) ELISA platform, which specifically has the cleaved form of PARP. It is expressed as an activation factor corresponding to the ratio of the amount of PARP cleaved in the treated mice divided by the amount of cleaved PARP in the control mice. The results show that the compounds of the invention are capable of inducing apoptosis of AMO-1 tumor cells in vivo.
[0025] EXAMPLE D In Vivo Anti-tumor Activity The anti-tumor activity of the compounds of the invention is evaluated in a model of AMO-1 multiple myeloma cell xenograft. 1.107 AMO-1 cells are grafted under the skin of immunocompromised mice (strain SCID). 6 to 8 days after the graft, when the tumor mass reached about 150 mm 3, the mice are treated with the various compounds according to a daily schedule (5-day treatment). The tumor mass is measured twice a week from the start of treatment. The results obtained using the 3.T / C ratio (i.e., the parameter of qualification of the activity of a product, which is defined as the ratio tumoral volume of the treated group / tumor volume of the untreated control group) show that the compounds of the invention induce significant regression of tumors during the treatment period.
[0026] EXAMPLE E: Pharmaceutical composition: Tablets 1000 tablets containing a dose of 5 mg of a compound selected from Examples 1 to 17 and Preparations 13 and 14 5g Wheat starch 20 g Corn starch 20 g Lactose 30 g Magnesium stearate 2 g

权利要求:
Claims (44)
[0001]
REVENDICATIONS1. Compounds of formula (I): Ra Rb (1) where: - A represents the group where 1 is bonded to the oxygen atom and 2 is bonded to the phenyl ring, - R1 represents a linear C1 to C6 alkyl group or branched, linear or branched C 2 -C 6 alkenyl group, linear or branched C 2 -C 6 alkynyl group, linear or branched C 1 -C 6 alkoxy group, -S- (C 1 -C 6) alkyl group, polyhaloalkyl group linear or branched C1-C6, a hydroxy group, a hydroxy (C1-C6) alkyl group, a cyano group, -Cy6 ora halogen atom, R2, R3, R4 and R5 represent independently of each other an atom Hydrogen, a halogen atom, a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a linear or branched C2-C6 alkynyl group, a C1-C6 polyhaloalkyl group; linear or branched, a Wroxy group, a hydroxy (alkyl) C1 to C6), a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group, a cyano group, a nitro group, - (C1-C6) alkyl -NR9R9 ' , -O- (C1-C6) alkyl -NR9R9 ', -O- (C1-C6) alkyl -R10, -C (O) -OR9, -OC (O) -R9, -C (O) - NR 9 R 9 ', -NR 9 -C (O) -R 9', 3037957 -47- -NR 9 -C (O) -OR 9 ', - (C 1 -C 6) alkyl -NR 9 -C (O) -R 9', -SO 2 -NR9R9 ', -SO2- (C1-C6) alkyl, or the substituents of one of the pairs (R2, R3), (R3, R4), (R4, R5), when they are grafted on two atoms of adjacent carbon atoms, together with the carbon atoms carrying them, form an aromatic or non-aromatic 5- to 7-membered ring which may contain from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, it being understood that the resulting ring may be substituted by a group selected from a linear or branched C1-C6 alkyl group, -NR1R '- (C1-C6) alkylCy1 or an oxo, and - R6 and R7 independently represent one of the other a hydrogen atom, a halogen atom, a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a linear or branched C2-C6 alkynyl group or a polyhaloalkyl group; C1 to C6 linear or branched, a hydroxyl group, a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group, a cyano group, a nitro group, - (C1-C6) alkyl ) -NR9R9 ', -O- (C1-C6) alkyl -NR9R9', -O-Cyj, -C6-C6alkyl-Cyl, -C2-C6alkenylCy1-, alkynyl- C2 to C6) -Cyl, -O- (C1-C6) alkyl-R10, -C (O) -OR9, -O-C (O) -R9, -C (O) -NR9R9 ', -NR9- C (O) -R9 ', -NR9-C (O) -OR9', - (C1-C6) alkyl -NR9-C (O) -R9 ', -SO2-NR9R9' or -SO2- (alkyl) C1 to C6), or the substituents of the pair (R6, R7), when grafted on two adjacent carbon atoms, together with the carbon atoms carrying them an aromatic or non-aromatic ring consisting of 5 to 7 linkers, which may contain from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, it being understood that the resulting ring may be substituted by a group selected from a linear or branched C1-C6 alkyl group, -NR11R11 - (C 1 -C 6 alkyl) -Cyi or an oxo, - R3 represents a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a linear C2-C6 alkynyl group or branched, -Cy3, a - (C1-C6) alkyl-Cy3, utr - (C2-C6) alkenyl-C3, a - (C2-C6 alkynyl) -Cy3, -Cy3-Cy4, a - (alkynyl) C1-C6) -O-Cy3, -Cy3- (C1-C6) alkyl-O- (C1-C6) alkyl -Cy4, halogen, cyano, -C (O) - R12 or -C (O) -NRI2R12 ', R9 and R9' represent, independently of each other, a hydrogen atom, a linear or branched C1-C6 alkyl group, a - (alkyl) in C6-C6) -CY1, or the substituents of the pair (R9, R9 ') form together with the nitrogen atom bearing them an aromatic or non-aromatic 5- to 7-membered ring which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom or a linear or branched C1-C6 alkyl group, and it being understood that the carbon atom (s) of the possible substituents may can be deuterated, - Rio represents -Cyl, -Cyl- (C6-C6) alkyl -Cy2, -Cyi- (C1-C6) alkyl-O- (C1-C6) alkyl -Cy2, -Cyi - (C1-C6) alkyl-NR9-C6-C6 alkyl-C y2, -C y -K2-O- (C1-C6) alkyl-C y5, -C (O) -NR9R9 ', -NR9R9' , -OR9, -NR9-C (O) -R9 ', -O- (C1-C6) alkyl-OR9, -SO2-R9, -C (O) -OR9 or -NH-C (O) -NH R 17, R 11, R 11 ', R 12 and R 12' represent independently of each other a hydrogen atom or an optionally linear or branched C1 to C6 alkyl group substituted, R13 represents a hydrogen atom, a hydroxy group or a hydroxy (C1-C6) alkyl group, - Ra represents a hydrogen atom or a linear or branched C1-C6 alkyl group, - Rb represents a group -O-C (O) -O-Ra, a group -O-C (O) -NR, Ra 'or a group -O-P (O) (ORa) 2, - R, and Ra' represent independently of one another a hydrogen atom, a linear or branched C1-C3 alkyl group, a cycloalkyl group, a (C1-C6) alkoxy (C1-C6) alkyl group, a C1-C6 alkoxy) carbonyl (C1-C6) alkyl, or the substituents of the (Ra, Ra ') pair together with the nitrogen atom carrying them a non-aromatic ring of 5 to 7 members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a C1-C6 alkyl group Invention or branching, Cy1, Cy2, Cy3, Cy4, Cys and Cy6 independently of one another represent a cycloalkyl group, a heterocycloalkyl group, an aryl group or a heteroaryl group, n is an integer of 0. or 1, it being understood that: - "aryl" means a phenyl, naphthyl, biphenyl, indanyl or indenyl group, - "heteroaryl" means any mono- or bi-cyclic group consisting of 5 to 10 members, possessing at least one aromatic group and containing from 10 to 3 heteroatoms chosen from oxygen, sulfur and nitrogen, "cycloalkyl" means any nonaromatic, mono- or bi-cyclic carbocyclic group containing from 3 to the term "heterocycloalkyl" is understood to mean any nonaromatic, mono- or bi-cyclic carbocyclic group consisting of from 3 to 10 ring members and containing from 1 to 3 heteroatoms chosen from oxygen, sulfur and nitrogen, which can include bridged, bridged or spiro ring systems, the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups thus defined, and the alkyl, alkenyl, alkynyl and alkoxy groups which may be substituted with 1 to 4 groups chosen from linear or optionally branched C1 to C6 alkyl; substituted, optionally substituted linear or branched C2 to C6 alkenyl, optionally substituted linear or branched C2 to C6 alkynyl, optionally substituted linear or branched C1 to C6 alkoxy, (C1 to C6) alkyl-S- optionally substituted, hydroxy , oxo (or N-oxide if appropriate), nitro, cyan, -C (O) -OR ', -O-C (O) -R', -C (O) -NR'R ", -NR ' R ", - (C = NR ') - OR", linear or branched C1-C6 polyhaloalkyl, trifluoromethoxy or halogen, it being understood that R' and R "represent, independently of one another, an atom of hydrogen or an optionally substituted linear or branched C1 to C6 alkyl group, and being wherein the carbon atom (s) of the foregoing substituents may be deuterated, their enantiomers, diastereoisomers and atropisomers, and their addition salts with a pharmaceutically acceptable acid or base. 3037957 -50-
[0002]
2. Compound of formula (I) according to claim 1, wherein at least one of groups selected from R2, R3, R4 and. R5 does not represent a hydrogen atom.
[0003]
3. Compound of formula (I) according to claim 1, wherein n is an integer equal to
[0004]
4. Compound of formula (I) according to claim 1, wherein RI represents a linear or branched C1-C6 alkyl group or a halogen atom. 10
[0005]
5. Compound of formula (I) according to claim 1, wherein RI3 represents a hydrogen atom.
[0006]
6. Compound of formula (I) according to claim 1, wherein R4 and R5 represent a hydrogen atom. 15
[0007]
A compound of formula (I) according to claim 1 wherein R1, R9 and R9 'are as defined in claim 1.
[0008]
8. A compound of formula (I) according to claim 1, wherein R9 'OÙ R9 and Ro' are as defined in claim 1. 5
[0009]
9. Compound of formula (I) according to claim 1, wherein the substituents of the pair (R1, R5) are identical and the substituents of the pair (R2, R4) are identical.
[0010]
10. A compound of formula (I) according to claim 1, wherein R6 represents an optionally substituted linear or branched C1-6 alkoxy group or a group -O- (C1-C6) alkyl-R10.
[0011]
11. Compound of formula (I) according to claim 1, wherein R7 represents a hydrogen atom. 15
[0012]
A compound of formula (I) according to claim 1 wherein R10 is as defined in claim 1.
[0013]
13. Compound of formula (I) according to claim 1, wherein R8 represents a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a C2-C6 alkynyl group. linear or branched, an aryl group or a heteroaryl group.
[0014]
14. A compound of formula (I) according to claim 1, wherein-lk.9 and R9 'are independently of each other a linear or branched C1-C6 alkyl group, or the substituents of the pair (R9 , R9 ') together with the nitrogen atom carrying them a 5- to 7-membered non-aromatic ring, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom or a linear or branched C 1 -C 6 alkyl group.
[0015]
A compound of formula (I) according to claim 1, wherein R10 is -Cy1, -Cy1- (C1-C6) alkyl-O- (C1-C6) alkyl-C2y or -C6-alkylC6-C6) - Cy2. 15
[0016]
16. A compound of formula (I) according to claim 1, wherein Cyl is preferably a heteroaryl group.
[0017]
17. A compound of formula (I) according to claim 1, wherein Cy2 is preferably a phenyl group, a pyridinyl group, a pyrazolyl group, a morpholinyl group, a furanyl group or a cyclopropyl group.
[0018]
18. A compound of formula (I) according to claim 1, wherein R10 represents -Cy1-Cy2 where Cy1 represents a pyrimidinyl group and Cy2 represents a phenyl group, a pyridinyl group, a pyrazolyl group, a morpholinyl group, a furanyl group or a cyclopropyl group.
[0019]
19. Compound of formula (I) according to claim 1, wherein Ra represents a hydrogen atom or a methyl group. 30
[0020]
A compound of formula (I) according to claim 1, wherein Rb is -O-C (O) -O- (C1-C8) alkyl; a -O-C (O) -O-cycloalkyl group; a group -O-C (O) -NR, Rc ', where Rc and independently of one another represent a hydrogen atom, a linear or branched (C1-C6) alkyl group, a (C1-C6) alkoxy (C1-C6) alkyl group, a (C1-C6) alkoxycarbonyl (C1-C6) alkyl group, or the substituents of the (Ra, Ra ') pair together with the a nitrogen atom bearing them a 5- to 7-membered non-aromatic ring which may additionally contain from 1 to 3 heteroatoms selected from oxygen and nitrogen; or a group -O-P (O) (OH) 2.
[0021]
Compounds according to claim 1 which are - (2R) -2 - [(5S) -5- {3-chloro-2-methyl-4- [2- (4-methylpiperazin-1-ypethoxy)] - Phenyl-6- (4-fluorophenylthieno [2,3-d] pyrimidin-4-yl] oxyl-3- (2- {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxylphenyl) propanoate; 1-Rmethoxycarbonyl) oxylethyl; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-4- [2- (4-methylpiperazin-1-yepethoxy) phenyl] -6- - (4-fluorophenyl) thieno [2,3-pyrimidin-4-yloxy] -3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxylphenyl) propanoate 1 - [(ethoxycarbonypoxy)] (2R) -2-R5Sa) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxyl-phenyl} -6- (4-fluorophenylthieno [2,3-d]) 1 - {[(propan-2-yloxy) carbonyl] oxyl ethyl d] pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxylphenyl) propanoate; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yepethoxy) phenyl} -6- (4-fluorophenyl) thieno [ 2,3-4 pyrimidin-4-ylioxy} -342- {[2- (2-methox 1-R-tert-butoxycarbonypoxylethyl- (2R) -2- {[(5Sa) -5- (3-chloro-2-methyl) -4- [2- (4-yl) pyrimidin-4-yl] methoxy} phenylpropanoate Methylpiperazin-1-ylethoxy] phenyl-6- (4-fluorophenylthieno [2,3-4pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-ylimethoxy} 1- {[(cyclopentyloxy) carbonyl] oxy} ethyl phenyl) propanoate; (2R) -2 - {[(5S, 7) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl} -6- (4- 1 - {[(octyloxy) carbonyl] oxy} ethyl fluorophenylthio [2,3-pyrimidin-4-yloxy] -3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxy} phenylpropanoate (2R) -2 - {[(5R) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl} -6- (4-fluorophenyl) thieno 1 - [(diinylcarbamoyl) oxy] ethyl [2,3-d] pyrimidin-4-yloxy-3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxy} phenyl) propanoate; (2R) -2 - [(5S) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl} -6- (4-fluorophenyl) 1 - [(diethylcarbamoyl) oxy] ethyl thieno [2,3-4-pyrimidin-4-yloxy] -3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxy} phenyl) propanoate; 1 - {[(2R) -2 - {[(5Sa) -] - {3-chloro-2-methyl-442- (4-methylpiperazin) 1-morpholin-4-carboxylate; 1-yl) ethoxy] phenyl} -6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yl-oxy} -3- (24- [2- methoxyphenylpyrimidin-4-yl] methoxyl phenyl) propanoyl] oxy} ethyl; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-yl) ethoxy] -phenyl} -6- (4- fluorophenyl) thieno [2,3-d] pyrimidin-4-yl] oxy} -3- (2- [2- (2-methoxyphenyl) -pyrimidin-4-yl} methoxy} phenyl) propanoate of 1- {[( 2-methoxyethyl) carbamoyl] oxy} ethyl; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-4- [2- (4-methylpiperazin-1-yl) ethoxy] -phenyl} -6- fluorophenyl) thieno [2,3-d] pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxy} phenyl) propanoate of 1- [bis (2-methoxyethyl) carbamoyl] oxy} ethyl; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-442- (4-methylpiperazin-1-ylethoxy) phenyl} -6- (4-fluorophenylthieno [2], 3 - [[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxyl phenyl) propanoate of 1 - {[(2-methoxy) -2-d] pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) -pyrimidin-4-yl] methoxyl oxoethyl) (methyl) carbamoyl] oxy} ethyl; (2R) -2 - {[(5S) -5- {3-chloro-2-methyl-4- [2- (4-methylpiperazin)}; 1-yepethoxy] phenyl-6- (4-fluorophenylthieno [2,3-d] pyrimidin-4-yl] oxy} -3 - (2 - {[2- (2-methoxyphenyl) pyrimidin-4-yl] methoxy} (Phosphonooxy) methyl phenyl) propanoate; (2R) -2 - {[5- {2,6-dimethyl-4- [2- (4-methylpiperazin-1-yepethoxy) phenyl} -6- 1 - [(ethoxycarbonypoxy] ethyl) fluorophenylthiopeno [2,3-d] pyrimidin-4-yl] oxy-3 - (2 - {[2- (2-methoxyphenyl) pyrimidin-4-yl] methoxylphenyl) propanoate; (2R) -2 - {[5- {3,5-Dichloro-2,6-dimethyl-442- (4-methylpiperazin-1-ylethoxy) phenyl] -6- (4-fluorophenyl) thieno 4-pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) -Pyrimidin-4-yl] methoxy} phe 1-Kethoxycarbonyl) oxylethyl propanoate; (2R) -2 - {[5- {2,6-dimethyl-4- [2- (4-methylpiperazin-1-ylethoxy) phenyl} -6- 1- [4- (dimethylcarbamoyl) oxy] ethyl (4-fluorophenylthieno [2,3-pyrimidin-4-yloxy] -3- (2 - {[2- (2-methoxyphenyl) pyrimidin-4-ylimethoxy) phenyl) propanoate; (2R) -2- [1- (3,5-Dichloro-2,6-dimethyl-442- (4-methylpiperazin-1-yl) ethoxy] phenyl] -6- (4-fluorophenyl) thieno [2, 1-Rdimethylcarbamoyloxylethyl 3 -ilpyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) pyrimidin-4-yl] methoxylphenyl) propanoate. 3037957 - 55 -
[0022]
22. Process for the preparation of a compound of formula (I) according to claim 1, characterized in that it uses, as starting compound, the compound of formula (II): A key Br 5 where A is such that defined for the formula (I) in which 1 is bonded to the chlorine atom and .2 is bonded to the bromine atom, said compound of formula (II) being subjected to coupling with a coi / IF-osé of Wherein R6, R7, R13 and n are as defined for formula (I), and Alk represents an optionally substituted linear or branched C1 to C6 alkyl group, to give the compound of formula (I) IV): R13. Where R6, R7, R13, A and n are as defined for formula (I), and Alk is as defined above, the compound of formula (IV) being further subjected to coupling with a compound of formula (V). Where R1, R2, R3, R4 and R5 are as defined for formula (I), and RB1 and RB2 represent a hydrogen atom, a C1-C8 alkyl group, C6 linear or branched, or RB1 and RB2 form with oxygen carrying an optionally methylated ring, to obtain the compound of formula (VI) (VI) wherein R1, R2, R3, R4> R5> R6, R7, R13, A and n are as defined for formula (I) and Alk is as defined above, the ester function Alk-OC (O) - of the compound of formula (VI) being hydrolyzed to give the carboxylic acid of formula Wherein R1, R2, R3, R4, R5, R6, R7, R13, A and n are as defined for formula (I), which is coupled to a compound of formula (I); compound of formula (VIII): ## STR5 ## wherein Ra and Rb are as defined for formula (I) to give the compound of formula (I), which can be purified by a separation technique. classic, which is converted, if desired, its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers by a conventional separation technique, it being understood that at any time deemed appropriate during the process described above, certain groups (hydroxy, amino, etc.) of the starting reagents or synthetic intermediates may be protected, then deprotected and functionalized for the purposes of the synthesis.
[0023]
23. Compound of formula (VIA), a particular case of the compound of formula (VI) according to claim 22: wherein R 2 ', R 3', R 4 'and R 5' represent independently of each other a halogen atom, a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a linear or branched C2-C6 alkynyl group, a linear or branched C1-C6 polyhaloalkyl, a hydroxy group, a hydroxy (C1-C6) alkyl group, a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group, a cyano group, a nitro group, - (alkyl) group, to C6-C6) -NR9R9 ', -O- (C1-C6) alkyl -NR9R9', -O- (C1-C6) alkyl-R10, -C (O) -OR9, Io -OC (O) -R9, -C (O) -NR9R9 ', -NR9-C (O) -R9', -NR9-C (O) -OR9 ', -C1-C6alkyl -NR9-C (O) - R9 ', -SO2-NR.9R9', -SO2- (C1-C6) alkyl, -T represents a C1-C6 alkyl group, a (C1-C6 carbonyloxy) (C1-C6) alkyl group; 1 to C6) or a di (C1-C6 alkyl) aminocarbonyl (C1-C6) alkyl group, wherein R1, R6, R7, R9, R9 ', R10, R13, A and n are as defined for formula (I), its enantiomers, diastereoisomers and atropisomers, and its addition salts with a pharmaceutically acceptable acid or base.
[0024]
24. A compound of formula (VIA) according to claim 2-1, wherein the substituents of the pair (R1, R5 ') are the same and the substituents of the pair (R2', R4 ') are identical.
[0025]
25. Compound of formula (VIIA), a particular case of the compound of formula (VII) according to claim 22, wherein: R2 ', R3', R4 'and R5' independently represent each other a halogen atom, a linear or branched C1-C6 alkyl group, a linear or branched C2-C6 alkenyl group, a linear or branched C2-C6 alkynyl group, a linear C1-C6 polyhaloalkyl group; or branched, a hydroxy group, a hydroxy (C1-C6) alkyl group, a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group, a cyano group, a nitro group, - (C1-C6) alkyl-NR9R9 ', -O- (C1-C6) alkyl-NR9R9', -O- (C1-C6) alkyl-R10, -C (O) -OR9, -OC (0) -R9, -C (O) -NR9R9 ', -NR9-C (O) -R9', -NR9-C (O) -OR9 ', -C1-C6alkyl -NR9-C ( 0) -R9 ', -SO2-NR9R9', -SO2- (C1-C6) alkyl, -R1, R6, R7, R9, R9 ', R10, R13, A and n are as defined for the formula ( I), his enant iomers, diastereoisomers and atropisomers, and its addition salts with a pharmaceutically acceptable acid or base.
[0026]
The fluoro compound (VIIA) according to claim 25, wherein the substituents of the (R1, R5 ') pair are identical and the substituents of the (R2', R4 ') pair are identical. 20
[0027]
27. Compound of formula (VIIA) according to claim 26, which is (2R) -2- {[5- {3,5-dichloro-2,6-dimethyl-442- (4-methylpiperazin-1-yl)} O-Ethoxylphenyl} -6- (4-fluorophenyl) thieno [2,3-d] pyrimidin-4-yl] oxy} -3- (2 - {[2- (2-methoxyphenyl) pyriinidin-4-yl] methoxy} phenyl ) propanoic 25
[0028]
28. A compound of formula (VIB), a particular case of the compound of formula (VI) according to claim 22, wherein: R5 'represents a halogen atom, a C1-C6 alkyl group linear or branched, a linear or branched C2-C6 alkenyl group, a linear or branched C2-C6 alkynyl group, a linear or branched C1-C6 polyhaloalkyl group, a hydroxy group, a hydroxy (C1-C6) alkyl group a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group, a cyano group, a nitro group, - (C1-C6) alkyl -NR9R9 ', -O- ( C1-C6 alkyl) -NR9R9 ', -O- (C1-C6) alkyl-R10, -C (O) -OR9, -OC (O) -R9, -C (O) -NR9R9', -NR9 -C (O) -R9 ', -NR9-C (O) -OR9', - (C1-C6) alkyl -NR9-C (O) -R9 ', -SO2-NR9R9', -SO2- (alkyl) C1 to C6), - T represents a C1-C6 alkyl group, a C1-C6 carbonyloxy (C1-C6) alkyl group or a di (C1-C6) alkylamino group; nocarbonyl (C1-C6) alkyl, R1, R3, R6, R7, R9, R9 ', R10, R13, A and n are as defined pottekrformule (I), and wherein the substituents of the pair (R1, R5' ) are identical, its enantiomers, diastereoisomers and atropisomers, and its addition salts with a pharmaceutically acceptable acid or base.
[0029]
29. Compound of formula (VIIB), a particular case of the compound of formula (VII) according to claim 22: wherein R5 'represents a halogen atom, a linear C1-C6 alkyl group or branched, a linear or branched C2-C6 alkenyl group, a linear or branched C2-C6 alkynyl group, a linear or branched C1-C6 polyhaloalkyl, a hydroxy group, a hydroxy (C1-C6) alkyl group a linear or branched C1-C6 alkoxy group, a -S- (C1-C6) alkyl group, a cyano group, a nitro group, - (C1-C6) alkyl -NR9R9 ', -O- (alkyl) C1 to C6) -NR9R9 ', -O- (C1-C6) alkyl-R10, -C (O) -OR9, -OC (O) -R9, -C (O) -NR9R9', -NR9 -C (O) -R9 ', -NR9-C (O) -OR9', - (C1-C6) alkyl -NR9-C (O) -R9 ', -SO2-NR9R9', -SO2- (alkyl) C1 to Co - R1, R3, R6, R7, R9, R9 ', R10, R13, A and n are as defined for formula (I), and wherein the substituents of the pair (R1, R5') are identical , 15 enantiomers, diastereoisomers and atropisomers, and its addition salts with a pharmaceutically acceptable acid or base.
[0030]
A compound of formula (VIIB) according to claim 29, which is (2R) -2 - {[5- {2,6-dimethyl-4- [4- (4-methylpiperazin-1-yl) ethoxy] phenyl] - 6- (4-Fluorophenyl) -thieno [2,3-d] pyrimidin-4-yl] oxy} -3424 [2- (2-methoxyphenyl) pyrimidin-4-ylmethoxyl-phexyl) propanoic acid.
[0031]
31. A pharmaceutical composition comprising a compound of formulas (I), (VIA), (VIB), (VITA) or (VIIB) according to any one of claims 1 to 21 or claims 23 to 30, or a salt thereof. addition thereof with a pharmaceutically acceptable acid or base in combination with one or more pharmaceutically acceptable excipients. 3037957 - 62 -
[0032]
32. The pharmaceutical composition of claim 31 for use as a pro-apoptotic agent. 5
[0033]
33. Pharmaceutical composition according to claim 32 for its use in the treatment of cancers and autoimmune diseases and the immune system.
[0034]
34. The pharmaceutical composition according to claim 33 for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemias, cancer of the colon, esophagus and liver. lymphoblastic leukemias, acute myeloid leukemias, lymphomas, melanomas, hematological malignancies, myelomas, ovarian cancer, non-small cell lung cancer, prostate cancer, pancreatic cancer, and cancer of the liver. small cell lung. 15
[0035]
35. Use of a pharmaceutical composition according to claim 31 in the manufacture of medicaments for use as pro-apoptotic agents.
[0036]
36. The use of a pharmaceutical composition according to claim 31 in the manufacture of medicaments for use in the treatment of cancer and autoimmune diseases and the immune system.
[0037]
37. Use of a pharmaceutical composition according to claim 31 in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemias, colon cancer, esophagus and liver, lymphoblastic leukemias, acute myeloid leukemias, lymphomas, melanomas, hematological malignancies, myelomas, ovarian cancer, non-small cell lung cancer, prostate cancer, pancreatic cancer and small cell lung cancer. 30
[0038]
38. A compound of formulas (I), (VIA), (VIB), (VITA) or (VIIB) according to any one of claims 1 to 21 or claims 23 to 30, or an addition salt thereof. with a pharmaceutically acceptable acid or base, for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemias, colon cancer, esophagus and liver, lymphoblastic leukemias, acute myeloid leukemias, lymphomas, melanomas, hematological malignancies, myelomas, ovarian cancer, non-small cell lung cancer, prostate cancer, cancer pancreas and small cell lung cancer.
[0039]
39. Use of a compound of formulas (I), (VIA), (VIB), (VITA) or (VIIB) according to 1-0 to any one of claims 1 to 21 or claims 23 to 30, or an addition salt thereof with a pharmaceutically acceptable acid or base, in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemias, colon cancer, esophagus and liver cancer, lymphoblastic leukemias, acute myeloid leukemias, lymphomas, melanomas, hematological malignancies, myelomas, ovarian cancer, non-small cell lung cancer, prostate cancer, pancreatic cancer and small cell lung cancer.
[0040]
40. Combination of a compound of formulas (I), (VIA), (VIB), (VIIA) or (VIIB) according to any one of claims 1 to 21 or claims 23 to 30 with an agent anti-cancer agent selected from genotoxic agents, mitotic poisons, antimetabolites, proteasome inhibitors, kinase inhibitors and antibodies.
[0041]
41. A pharmaceutical composition comprising a combination of claim 40 in combination with one or more pharmaceutically acceptable excipients.
[0042]
42. Association according to claim 40 for its use in the treatment of cancers. 30
[0043]
43. Use of an association according to claim 40 in the manufacture of medicaments for use in the treatment of cancers. 3037957 - 64 -
[0044]
44. A compound of formulas (I), (VIA), (VIB), (VIIA) or (VIIB) according to any one of claims 1 to 21 or claims 23 to 30 for use in the treatment of cancer requiring radiotherapy.

类似技术:

---

公开号 | 公开日 | 专利标题

---

FR3037957A1|2016-12-30|

---

EP3313817B1|2020-09-16|Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them

---

RU2743098C2|2021-02-15|Novel ammonium derivatives, a method for production thereof and pharmaceutical compositions containing them

---

FR3037958A1|2016-12-30|

---

FR3037956A1|2016-12-30|

---

EP2829545B1|2016-06-22|New phosphate derivatives, method of preparing same and pharmaceutical compositions containing them

---

FR3015483A1|2015-06-26|NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

---

EP3027602B1|2018-06-13|Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same

---

FR3061177B1|2019-09-27|NOVEL HETERO | -SUBSTITUTED PIPERIDINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

---

OA18889A|2019-09-30|New Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.

---

OA19003A|2019-11-22|New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them

同族专利:

---

公开号 | 公开日

---

JP2018522855A|2018-08-16|

---

IL256270D0|2018-02-28|

---

RS59904B1|2020-03-31|

---

CN107709333A|2018-02-16|

---

SI3313851T1|2020-03-31|

---

FR3037957B1|2019-01-25|

---

AR105103A1|2017-09-06|

---

PE20180742A1|2018-04-27|

---

EP3313851B1|2019-11-06|

---

US20180170947A1|2018-06-21|

---

RU2018102365A3|2019-09-23|

---

US10711010B2|2020-07-14|

---

CN107709333B|2021-01-01|

---

ECSP17081744A|2018-02-28|

---

CO2017012786A2|2018-04-10|

---

PH12017502246A1|2018-05-28|

---

EA201890125A1|2018-06-29|

---

PL3313851T3|2020-05-18|

---

HK1249506A1|2018-11-02|

---

CL2017003258A1|2018-06-01|

---

BR112017027414A2|2018-08-28|

---

TN2017000511A1|2019-04-12|

---

UY36736A|2016-12-30|

---

SV2017005587A|2018-04-11|

---

US10227358B2|2019-03-12|

---

UA122228C2|2020-10-12|

---

CA2990088A1|2016-12-29|

---

GEP20207074B|2020-03-10|

---

PT3313851T|2020-01-06|

---

AU2016282836B2|2020-07-09|

---

MX2017016997A|2018-09-07|

---

CU20170160A7|2018-05-08|

---

MD3313851T2|2020-02-29|

---

HUE047889T2|2020-05-28|

---

EP3313851A1|2018-05-02|

---

PH12017502246B1|2018-05-28|

---

JP6741697B2|2020-08-19|

---

ES2759480T3|2020-05-11|

---

WO2016207225A1|2016-12-29|

---

KR20180019223A|2018-02-23|

---

AU2016282836A1|2018-01-18|

---

CR20170564A|2018-02-20|

---

US20190161496A1|2019-05-30|

---

MA42239B1|2020-02-28|

---

HRP20200107T1|2020-04-03|

---

TWI604844B|2017-11-11|

---

EA033266B1|2019-09-30|

---

JO3675B1|2020-08-27|

---

RU2734418C2|2020-10-16|

---

ZA201708460B|2021-06-30|

---

CA2990088C|2021-04-13|

---

TW201709911A|2017-03-16|

---

RU2018102365A|2019-07-23|

---

DK3313851T3|2020-01-27|

---

HK1254657A1|2019-07-26|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

CN102464667B|2010-11-03|2014-06-04|中国科学院上海药物研究所|Five-membered heterocycle pyrimidine compounds, preparation method and application thereof|

---

WO2013072694A1|2011-11-15|2013-05-23|Xention Limited|Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors|

---

EP2886545A1|2013-12-23|2015-06-24|Les Laboratoires Servier|New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

ES2217956B1|2003-01-23|2006-04-01|Almirall Prodesfarma, S.A.|NEW DERIVATIVES OF 4-AMINOTIENE PIRIMIDIN-6-CARBONITRILE.|

---

WO2005021552A1|2003-08-29|2005-03-10|Vernalis Ltd|Pyrimidothiophene compounds|

---

NZ589336A|2008-03-05|2011-12-22|Methylgene Inc|Pyridine derivatives as inhibitors of protein tyrosine kinase activity|FR3037958B1|2015-06-23|2019-01-25|Les Laboratoires Servier|NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

TW201806600A|2016-07-22|2018-03-01|法商施維雅藥廠|Combination of a BCL-2 inhibitor and a MCL1 inhibitor, uses and pharmaceutical compositions thereof|

---

EP3567043A4|2017-01-05|2020-12-02|Henan Genuine Biotech Co., Ltd.|Thienopyrimidine derivative, preparation method therefor, and application thereof in manufacturing of antitumor drugs|

---

UA125142C2|2017-01-06|2022-01-19|Ле Лаборатуар Сервьє|Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof|

---

UY37560A|2017-01-06|2018-07-31|Servier Lab|COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS|

---

UY37777A|2017-06-22|2019-01-31|Servier Lab|COMBINATION OF AN MCL-1 INHIBITOR AND A STANDARD CARE TREATMENT FOR HEMATOLOGICAL CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS|

---

AU2018316620A1|2017-08-15|2020-03-12|AbbVie Deutschland GmbH & Co. KG|Macrocyclic MCL-1 inhibitors and methods of use|

---

CN111372936A|2017-11-23|2020-07-03|北京赛林泰医药技术有限公司|Mcl-1 selective inhibitors, their preparation and use|

---

CN108424417B|2017-12-21|2019-09-20|河南真实生物科技有限公司|Thienopyrimidine derivative, preparation method and application in preparation of anti-tumor drugs|

---

CN110964034A|2018-09-29|2020-04-07|江苏恒瑞医药股份有限公司|Pyrimidothiophene derivative, preparation method and medical application thereof|

---

TW202038960A|2018-11-14|2020-11-01|法商施維雅藥廠|Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof|

---

CN111187277A|2018-11-14|2020-05-22|江苏恒瑞医药股份有限公司|Thienopyrimidine derivative, preparation method and medical application thereof|

---

WO2020115183A1|2018-12-06|2020-06-11|Les Laboratoires Servier|New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.|

---

AU2020279979A1|2019-05-20|2021-11-25|Les Laboratoires Servier|Mcl-1 inhibitor antibody-drug conjugates and methods of use|

---

WO2020254299A1|2019-06-17|2020-12-24|Les Laboratoires Servier|Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof|

---

WO2021067827A1|2019-10-03|2021-04-08|California Institute Of Technology|Mcl1 inhibitors and uses thereof|

法律状态:
2016-06-28| PLFP| Fee payment|Year of fee payment: 2 |

---

2016-12-30| PLSC| Search report ready|Effective date: 20161230 |

---

2017-06-27| PLFP| Fee payment|Year of fee payment: 3 |

---

2018-06-26| PLFP| Fee payment|Year of fee payment: 4 |

---

2020-06-22| PLFP| Fee payment|Year of fee payment: 6 |

优先权:

---

申请号 | 申请日 | 专利标题

---

FR1555752|2015-06-23|

---

FR1555752A|FR3037957B1|2015-06-23|2015-06-23|NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME|FR1555752A| FR3037957B1|2015-06-23|2015-06-23|NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME|

---

UY0001036736A| UY36736A|2015-06-23|2016-06-16|NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

US15/737,479| US10227358B2|2015-06-23|2016-06-22|Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

MDE20180444T| MD3313851T2|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

TW105119605A| TWI604844B|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

RS20200136A| RS59904B1|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

ES16733379T| ES2759480T3|2015-06-23|2016-06-22|Novel hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

EA201890125A| EA033266B1|2015-06-23|2016-06-22|Hydroxyester derivatives, process for their preparation and pharmaceutical compositions containing them|

---

TNP/2017/000511A| TN2017000511A1|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.|

---

AU2016282836A| AU2016282836B2|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

KR1020187002033A| KR20180019223A|2015-06-23|2016-06-22|Novel hydroxy ester derivatives, processes for their preparation and pharmaceutical compositions containing them|

---

CUP2017000160A| CU20170160A7|2015-06-23|2016-06-22|DERIVADOSDE FENIL-TIENOPIRIMIDINA- HIDROXI-ESTERES, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT|

---

SI201630625T| SI3313851T1|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

GEAP201614678A| GEP20207074B|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

BR112017027414-0A| BR112017027414A2|2015-06-23|2016-06-22|HYDROXYSTER DERIVATIVES, PROCESS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

JOP/2016/0128A| JO3675B1|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

MX2017016997A| MX2017016997A|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.|

---

PE2017002534A| PE20180742A1|2015-06-23|2016-06-22|NEW HYDROXIESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

CR20170564A| CR20170564A|2015-06-23|2016-06-22|NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

PL16733379T| PL3313851T3|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

CA2990088A| CA2990088C|2015-06-23|2016-06-22|Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

DK16733379.8T| DK3313851T3|2015-06-23|2016-06-22|NEW HYDROXYESTER DERIVATIVES, A PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE|

---

CN201680036383.5A| CN107709333B|2015-06-23|2016-06-22|Hydroxy ester derivatives, process for their preparation and pharmaceutical compositions containing them|

---

RU2018102365A| RU2734418C2|2015-06-23|2016-06-22|Novel hydroxy-ester derivatives, a method for production thereof and pharmaceutical compositions containing them|

---

JP2017566271A| JP6741697B2|2015-06-23|2016-06-22|Novel hydroxy ester derivative, method for preparing the same and pharmaceutical composition containing the same|

---

HUE16733379A| HUE047889T2|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

PT167333798T| PT3313851T|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

PCT/EP2016/064433| WO2016207225A1|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

MA42239A| MA42239B1|2015-06-23|2016-06-22|New hydroxyester derivatives, their preparation process and pharmaceutical compositions containing them|

---

UAA201800618A| UA122228C2|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

EP16733379.8A| EP3313851B1|2015-06-23|2016-06-22|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

ARP160101881A| AR105103A1|2015-06-23|2016-06-23|HYDROXYESTER DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

PH12017502246A| PH12017502246B1|2015-06-23|2017-12-07|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

SV2017005587A| SV2017005587A|2015-06-23|2017-12-12|NEW HYDROXIESTER DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

IL256270A| IL256270D0|2015-06-23|2017-12-12|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

ECIEPI201781744A| ECSP17081744A|2015-06-23|2017-12-12|NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM|

---

ZA2017/08460A| ZA201708460B|2015-06-23|2017-12-13|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

CONC2017/0012786A| CO2017012786A2|2015-06-23|2017-12-13|New hydroxy ester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

CL2017003258A| CL2017003258A1|2015-06-23|2017-12-18|New hydroxy ester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

HK18109026.9A| HK1249506A1|2015-06-23|2018-07-11|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containging them|

---

HK18113625.6A| HK1254657A1|2015-06-23|2018-10-24|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

US16/247,614| US10711010B2|2015-06-23|2019-01-15|Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|

---

HRP20200107TT| HRP20200107T1|2015-06-23|2020-01-23|New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them|